JP2013095708A - Medusa collagen peptide mixture - Google Patents
Medusa collagen peptide mixture Download PDFInfo
- Publication number
- JP2013095708A JP2013095708A JP2011240469A JP2011240469A JP2013095708A JP 2013095708 A JP2013095708 A JP 2013095708A JP 2011240469 A JP2011240469 A JP 2011240469A JP 2011240469 A JP2011240469 A JP 2011240469A JP 2013095708 A JP2013095708 A JP 2013095708A
- Authority
- JP
- Japan
- Prior art keywords
- gly
- pro
- jellyfish
- collagen
- jellyfish collagen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000008186 Collagen Human genes 0.000 title claims abstract description 239
- 108010035532 Collagen Proteins 0.000 title claims abstract description 239
- 229920001436 collagen Polymers 0.000 title claims abstract description 239
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 159
- 239000000203 mixture Substances 0.000 title claims abstract description 84
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 42
- MYXNLWDWWOTERK-BHNWBGBOSA-N Gly-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)CN)O MYXNLWDWWOTERK-BHNWBGBOSA-N 0.000 claims abstract description 20
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims abstract description 6
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229960002591 hydroxyproline Drugs 0.000 claims abstract description 6
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 claims abstract description 6
- 241000242583 Scyphozoa Species 0.000 claims description 185
- 239000003054 catalyst Substances 0.000 claims description 38
- 239000011973 solid acid Substances 0.000 claims description 37
- 102000057297 Pepsin A Human genes 0.000 claims description 25
- 108090000284 Pepsin A Proteins 0.000 claims description 25
- 238000006460 hydrolysis reaction Methods 0.000 claims description 25
- 229940111202 pepsin Drugs 0.000 claims description 25
- 238000002360 preparation method Methods 0.000 claims description 25
- 230000007062 hydrolysis Effects 0.000 claims description 24
- 238000004519 manufacturing process Methods 0.000 claims description 24
- 102000004190 Enzymes Human genes 0.000 claims description 21
- 108090000790 Enzymes Proteins 0.000 claims description 21
- 229940088598 enzyme Drugs 0.000 claims description 21
- 239000004365 Protease Substances 0.000 claims description 18
- 102000007236 involucrin Human genes 0.000 claims description 18
- 108010033564 involucrin Proteins 0.000 claims description 18
- 102000004142 Trypsin Human genes 0.000 claims description 16
- 108090000631 Trypsin Proteins 0.000 claims description 16
- 210000002510 keratinocyte Anatomy 0.000 claims description 16
- 239000012588 trypsin Substances 0.000 claims description 16
- 229960001322 trypsin Drugs 0.000 claims description 16
- 108090000526 Papain Proteins 0.000 claims description 15
- 230000000593 degrading effect Effects 0.000 claims description 15
- 230000003301 hydrolyzing effect Effects 0.000 claims description 15
- 235000019834 papain Nutrition 0.000 claims description 15
- 229940055729 papain Drugs 0.000 claims description 15
- 108060008539 Transglutaminase Proteins 0.000 claims description 12
- 102000003601 transglutaminase Human genes 0.000 claims description 12
- 150000001768 cations Chemical class 0.000 claims description 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 6
- 229910021536 Zeolite Inorganic materials 0.000 claims description 6
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 claims description 6
- 239000010457 zeolite Substances 0.000 claims description 6
- 239000005909 Kieselgur Substances 0.000 claims description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 5
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 5
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 5
- 239000012190 activator Substances 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 33
- 230000004888 barrier function Effects 0.000 abstract description 8
- 230000008439 repair process Effects 0.000 abstract description 3
- 230000007935 neutral effect Effects 0.000 description 29
- 102000004196 processed proteins & peptides Human genes 0.000 description 28
- 239000002537 cosmetic Substances 0.000 description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 20
- 210000003491 skin Anatomy 0.000 description 18
- 239000000243 solution Substances 0.000 description 18
- 230000002378 acidificating effect Effects 0.000 description 17
- 150000001413 amino acids Chemical class 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 239000002609 medium Substances 0.000 description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- -1 ethanol Chemical compound 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 238000010438 heat treatment Methods 0.000 description 12
- 230000000670 limiting effect Effects 0.000 description 12
- 230000003110 anti-inflammatory effect Effects 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000007864 aqueous solution Substances 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 230000001737 promoting effect Effects 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 238000004949 mass spectrometry Methods 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 239000000047 product Substances 0.000 description 7
- 241000242567 Aurelia aurita Species 0.000 description 6
- 108010076876 Keratins Proteins 0.000 description 6
- 102000011782 Keratins Human genes 0.000 description 6
- 102100030944 Protein-glutamine gamma-glutamyltransferase K Human genes 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000010261 cell growth Effects 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 210000000434 stratum corneum Anatomy 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 108010058734 transglutaminase 1 Proteins 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 239000003788 bath preparation Substances 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 239000011148 porous material Substances 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- MEYZIGGCNFHINA-UHFFFAOYSA-N (6-aminoquinolin-2-yl) n-(2,5-dioxopyrrolidin-1-yl)-n-hydroxycarbamate Chemical compound C1=CC2=CC(N)=CC=C2N=C1OC(=O)N(O)N1C(=O)CCC1=O MEYZIGGCNFHINA-UHFFFAOYSA-N 0.000 description 4
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 235000005956 Cosmos caudatus Nutrition 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 102000035195 Peptidases Human genes 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 125000002947 alkylene group Chemical group 0.000 description 4
- FUWUEFKEXZQKKA-UHFFFAOYSA-N beta-thujaplicin Chemical compound CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 239000003729 cation exchange resin Substances 0.000 description 4
- 238000000354 decomposition reaction Methods 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 239000007790 solid phase Substances 0.000 description 4
- 238000001179 sorption measurement Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 3
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 238000003277 amino acid sequence analysis Methods 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 230000020411 cell activation Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000002738 chelating agent Substances 0.000 description 3
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 230000003020 moisturizing effect Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 235000019419 proteases Nutrition 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 239000006097 ultraviolet radiation absorber Substances 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical class C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 235000018330 Macadamia integrifolia Nutrition 0.000 description 2
- 240000000912 Macadamia tetraphylla Species 0.000 description 2
- 235000003800 Macadamia tetraphylla Nutrition 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- TUFYVOCKVJOUIR-UHFFFAOYSA-N alpha-Thujaplicin Natural products CC(C)C=1C=CC=CC(=O)C=1O TUFYVOCKVJOUIR-UHFFFAOYSA-N 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 239000013040 bath agent Substances 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 238000005341 cation exchange Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000011033 desalting Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 210000000245 forearm Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 229940119170 jojoba wax Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- 239000010466 nut oil Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- JMANVNJQNLATNU-UHFFFAOYSA-N oxalonitrile Chemical compound N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 125000001174 sulfone group Chemical group 0.000 description 2
- 238000004885 tandem mass spectrometry Methods 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 229930007845 β-thujaplicin Natural products 0.000 description 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 241000242764 Aequorea victoria Species 0.000 description 1
- 241001504639 Alcedo atthis Species 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 235000018185 Betula X alpestris Nutrition 0.000 description 1
- 235000018212 Betula X uliginosa Nutrition 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 240000006432 Carica papaya Species 0.000 description 1
- 235000009467 Carica papaya Nutrition 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- 241000242741 Cubozoa Species 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000011891 EIA kit Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000009429 Ginkgo biloba extract Substances 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000243320 Hydrozoa Species 0.000 description 1
- 241000832224 Hypericaceae Species 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 102100031784 Loricrin Human genes 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241001429712 Mitrocoma cellularia Species 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 229920000557 Nafion® Polymers 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 239000006002 Pepper Substances 0.000 description 1
- 108010047320 Pepsinogen A Proteins 0.000 description 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
- 235000016761 Piper aduncum Nutrition 0.000 description 1
- 235000017804 Piper guineense Nutrition 0.000 description 1
- 244000203593 Piper nigrum Species 0.000 description 1
- 235000008184 Piper nigrum Nutrition 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241000124033 Salix Species 0.000 description 1
- 241000239226 Scorpiones Species 0.000 description 1
- 208000006981 Skin Abnormalities Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 241001371096 Staurozoa Species 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102000018690 Trypsinogen Human genes 0.000 description 1
- 108010027252 Trypsinogen Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000010477 apricot oil Substances 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000021302 avocado oil Nutrition 0.000 description 1
- 239000008163 avocado oil Substances 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 150000008366 benzophenones Chemical class 0.000 description 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 1
- 239000012964 benzotriazole Substances 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000010495 camellia oil Substances 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229940124568 digestive agent Drugs 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- REZZEXDLIUJMMS-UHFFFAOYSA-M dimethyldioctadecylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC REZZEXDLIUJMMS-UHFFFAOYSA-M 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 239000004664 distearyldimethylammonium chloride (DHTDMAC) Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- UQSQSQZYBQSBJZ-UHFFFAOYSA-N fluorosulfonic acid Chemical compound OS(F)(=O)=O UQSQSQZYBQSBJZ-UHFFFAOYSA-N 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940068052 ginkgo biloba extract Drugs 0.000 description 1
- 235000020686 ginkgo biloba extract Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000008169 grapeseed oil Substances 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 229920013821 hydroxy alkyl cellulose Polymers 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 108010079309 loricrin Proteins 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 229940068041 phytic acid Drugs 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 239000000467 phytic acid Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 229940109850 royal jelly Drugs 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000011949 solid catalyst Substances 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229940104261 taurate Drugs 0.000 description 1
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 1
- DZLFLBLQUQXARW-UHFFFAOYSA-N tetrabutylammonium Chemical compound CCCC[N+](CCCC)(CCCC)CCCC DZLFLBLQUQXARW-UHFFFAOYSA-N 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 239000012929 tonicity agent Substances 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000004711 α-olefin Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/12—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by hydrolysis, i.e. solvolysis in general
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43595—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from coelenteratae, e.g. medusae
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Analytical Chemistry (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Cosmetics (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
本発明は、特定のアミノ酸配列を含むクラゲコラーゲンペプチド混合物に関する。また、該クラゲコラーゲンペプチドを含有する外用剤に関し、特に、角化細胞賦活剤、インボルクリン産生促進剤、トランスグルタミナーゼ産生促進剤及び/または抗炎症剤としての外用剤に関する。 The present invention relates to a jellyfish collagen peptide mixture comprising a specific amino acid sequence. The present invention also relates to an external preparation containing the jellyfish collagen peptide, and particularly to an external preparation as a keratinocyte activator, an involucrin production promoter, a transglutaminase production promoter and / or an anti-inflammatory agent.
近年、日本近海におけるクラゲの大量発生が社会問題化しており、大量発生したエチゼンクラゲが漁網を破損し、漁獲量を低下させるなど漁業に深刻なダメージを与えている。またミズクラゲやエチゼンクラゲが工場や火力発電所、原子力発電所の取水口に詰まるなどの被害も生じている。大量発生したクラゲは、主に捕獲駆除されているものの、捕獲したクラゲの廃棄にもコストを要するため、捕獲駆除に替わる有効な解決手段が各方面から望まれていた。 In recent years, the mass outbreak of jellyfish in the seas near Japan has become a social problem, and the large amount of echidella jellyfish has damaged the fishing nets and has caused serious damage to the fishery. There are also damages such as water jellyfish and Echizen jellyfish clogging water intakes in factories, thermal power plants, and nuclear power plants. Although a large amount of jellyfish are mainly captured and exterminated, it is costly to dispose of the captured jellyfish. Therefore, an effective solution to capture and extinguishment has been desired from various directions.
その対策のひとつに、クラゲのコラーゲン原料としての利用が提案されている。 As one of the countermeasures, use of jellyfish as a collagen raw material has been proposed.
基礎化粧料の重要なアイテムであるコラーゲンは、主に牛や豚などの哺乳動物に由来するものが用いられており、哺乳動物はタンパク質の1/3がコラーゲンであるとされている。それに対し、クラゲは95〜98質量%の水分と、2〜5質量%の固形物からなり、この固形物の20〜30質量%がタンパク質であり、その80質量%がコラーゲンであるといわれている。 Collagen, which is an important item of basic cosmetics, is mainly derived from mammals such as cows and pigs. In mammals, 1/3 of protein is collagen. On the other hand, jellyfish is composed of 95 to 98% by weight of water and 2 to 5% by weight of solids, 20 to 30% by weight of these solids being protein, and 80% by weight being collagen. Yes.
一般に、哺乳動物由来のコラーゲンが、動物の皮膚や骨などの硬い組織からの抽出物であるのに対し、大量の水分を含む軟らかい組織で構成されているクラゲのコラーゲンには、他の動物性コラーゲンにはない機能や活性があるものと予想される。 In general, mammal-derived collagen is an extract from hard tissues such as animal skin and bone, whereas jellyfish collagen composed of soft tissues containing a large amount of water has other animal properties. Expected to have functions and activities not found in collagen.
クラゲ抽出物に関する検討として、ミズクラゲやエチゼンクラゲから得られた液状物を皮膚外用剤に配合して使用することにより、肌の水分保持能が更新され、角層のターンオーバーを正常化できるとの報告がある(特許文献1)。しかし、クラゲから得られた液状物、すなわちクラゲコラーゲンを含むタンパク質による表皮細胞賦活効果は、十分満足できるものではなかった。 As a study on jellyfish extract, it is reported that the liquid retention obtained from moon jellyfish and Echizen jellyfish can be used in skin preparations to renew the moisture retention capacity of the skin and normalize the turnover of the stratum corneum. (Patent Document 1). However, the liquid substance obtained from jellyfish, that is, the epidermal cell activation effect by the protein containing jellyfish collagen was not fully satisfactory.
皮膚は乾燥、紫外線などの物理的刺激から内部の細胞を保護し、体内成分の喪失を防止する役目をはたしている。この機能は皮膚のバリア機能または角質のバリア機能と呼ばれ、その機能の重要な役目を担っているのが角層である。 The skin protects internal cells from physical stimuli such as dryness and ultraviolet rays, and prevents the loss of internal components. This function is called a skin barrier function or horny barrier function, and the stratum corneum plays an important role in this function.
角層は表皮角化細胞が分化して形成された角質層と、細胞間を埋める細胞間脂質から形成されたものであり、角質層はケラチン繊維とコーニファイドエンベロープ(CE)から構成され、CEはインボルクリンや、ロリクリンなどがトランスグルタミナーゼ1などの酵素により架橋して形成されたものである。角質のバリア機能は、CEの一部と細胞間脂質であるセラミドなどが共有結合して形成されることが知られており、角質のバリア機能を改善するには、表皮角化細胞の増殖、インボルクリン、トランスグルタミナーゼの増加が重要と考えられている。 The stratum corneum is formed from a stratum corneum formed by differentiation of epidermal keratinocytes and intercellular lipids filling the cells, and the stratum corneum is composed of keratin fibers and a conformed envelope (CE). Is formed by crosslinking involucrin, loricrin, or the like with an enzyme such as transglutaminase 1. It is known that the keratin barrier function is formed by covalently binding a part of CE and ceramide, which is an intercellular lipid. To improve the keratin barrier function, the proliferation of epidermal keratinocytes, Increases in involucrin and transglutaminase are considered important.
インボルクリン産生促進効果、トランスグルタミナーゼ産生促進効果については、オトギリソウ科セイロンテツボク、シラカンバ、ローヤルゼリーなど天然物及びそのエキス類による効果が報告されている(特許文献2、3、4)。しかし、クラゲコラーゲンペプチ
ドの表皮細胞の賦活化効果、インボルクリン、トランスグルタミナーゼ産生促進効果については、これまで報告されていない。
As for the involucrin production promoting effect and the transglutaminase production promoting effect, the effects of natural products such as hypericaceae Ceylon tetsuboku, birch, royal jelly, and extracts thereof have been reported (
本発明は、角質のバリア機能の修復改善効果を有するクラゲコラーゲンペプチド混合物の提供を目的とする。 An object of the present invention is to provide a jellyfish collagen peptide mixture having an effect of improving the repair of the keratin barrier function.
本発明者らは、上記課題を解決するために鋭意検討を行った結果、特定のアミノ酸配列を含むクラゲコラーゲンペプチドの混合物に、優れた表皮角化細胞賦活効果、インボルクリン産生促進効果、トランスグルタミナーゼ産生促進効果、抗炎症効果を見出し、この知見に基づき本発明を完成するに到った。これらの効果により、角質のバリア機能を修復し、改善することが可能となる。 As a result of intensive studies to solve the above problems, the present inventors have found that a mixture of jellyfish collagen peptides containing a specific amino acid sequence has an excellent epidermal keratinocyte activation effect, involucrin production promoting effect, transglutaminase production The present inventors have found a promoting effect and an anti-inflammatory effect, and have completed the present invention based on this finding. These effects make it possible to repair and improve the keratin barrier function.
即ち、本発明は下記の(1)〜(13)に係わるものである。
(1)下記アミノ酸配列のいずれかを含むクラゲコラーゲンペプチドを含有するクラゲコラーゲンペプチド混合物。
That is, the present invention relates to the following (1) to (13).
(1) A jellyfish collagen peptide mixture containing a jellyfish collagen peptide containing any of the following amino acid sequences.
<1>Gly-Pro-Ala-Gly(配列番号1)
<2>Pro-Gly-Val-Lys-Gly-Glu-Val-Gly-Glu-Ala-Gly-Lys-Arg-Gly(配列番号2)
<3>Val-Gly-Pro-Val-Thr-Glu-Glu-Val-Ser-Pro-Ala-Lys(配列番号3)
<4>Ser-Ala-Gly-Gln-Asn-Pro-Ala-Asp-Asp-Val(配列番号4)
<5>Gly-Thr-Pro(OH)-Gly-Ala-Gly-Gly-Ser-Arg(配列番号5)
<6>Gln-Gly-Pro-Gln-Gly-Glu-Leu(配列番号6)
Pro(OH)はヒドロキシプロリンを示す。
<1> Gly-Pro-Ala-Gly (SEQ ID NO: 1)
<2> Pro-Gly-Val-Lys-Gly-Glu-Val-Gly-Glu-Ala-Gly-Lys-Arg-Gly (SEQ ID NO: 2)
<3> Val-Gly-Pro-Val-Thr-Glu-Glu-Val-Ser-Pro-Ala-Lys (SEQ ID NO: 3)
<4> Ser-Ala-Gly-Gln-Asn-Pro-Ala-Asp-Asp-Val (SEQ ID NO: 4)
<5> Gly-Thr-Pro (OH) -Gly-Ala-Gly-Gly-Ser-Arg (SEQ ID NO: 5)
<6> Gln-Gly-Pro-Gln-Gly-Glu-Leu (SEQ ID NO: 6)
Pro (OH) represents hydroxyproline.
(2)クラゲコラーゲンを加水分解して得られる項1に記載のクラゲコラーゲンペプチド混合物。 (2) The jellyfish collagen peptide mixture according to item 1, obtained by hydrolyzing jellyfish collagen.
(3)加水分解をトリプシン、ペプシン、パパインからなる群より選ばれた少なくとも1種のペプチド分解酵素を用いて行うことを特徴とする項2に記載のクラゲコラーゲンペプチド混合物。
(3) The jellyfish collagen peptide mixture according to
(4)加水分解を固体酸触媒を用いて行うことを特徴とする項2に記載のクラゲコラーゲンペプチド混合物。
(4) The jellyfish collagen peptide mixture according to
(5)固体酸触媒が、陽イオン交換体、ゼオライト、珪藻土からなる群より選ばれた少なくとも1種の固体酸触媒であることを特徴とする項4に記載のクラゲコラーゲンペプチド混合物。 (5) The jellyfish collagen peptide mixture according to item 4, wherein the solid acid catalyst is at least one solid acid catalyst selected from the group consisting of a cation exchanger, zeolite, and diatomaceous earth.
(6)クラゲコラーゲンが、ミズクラゲコラーゲンまたはエチゼンクラゲコラーゲンである項1〜5のいずれか1項に記載のクラゲコラーゲンペプチド混合物。 (6) The jellyfish collagen peptide mixture according to any one of Items 1 to 5, wherein the jellyfish collagen is a moon jellyfish collagen or an Echizen jellyfish collagen.
(7)クラゲコラーゲンを、ペプチド分解酵素または固体酸触媒を用いて加水分解することにより得られる、クラゲコラーゲンペプチド混合物。 (7) A jellyfish collagen peptide mixture obtained by hydrolyzing jellyfish collagen using a peptide degrading enzyme or a solid acid catalyst.
(8)下記アミノ酸配列のいずれかを含むペプチド。 (8) A peptide comprising any of the following amino acid sequences.
<1>Gly-Pro-Ala-Gly(配列番号1)
<2>Pro-Gly-Val-Lys-Gly-Glu-Val-Gly-Glu-Ala-Gly-Lys-Arg-Gly(配列番号2)
<3>Val-Gly-Pro-Val-Thr-Glu-Glu-Val-Ser-Pro-Ala-Lys(配列番号3)
<4>Ser-Ala-Gly-Gln-Asn-Pro-Ala-Asp-Asp-Val(配列番号4)
<5>Gly-Thr-Pro(OH)-Gly-Ala-Gly-Gly-Ser-Arg(配列番号5)
<6>Gln-Gly-Pro-Gln-Gly-Glu-Leu(配列番号6)
Pro(OH)はヒドロキシプロリンを示す。
<1> Gly-Pro-Ala-Gly (SEQ ID NO: 1)
<2> Pro-Gly-Val-Lys-Gly-Glu-Val-Gly-Glu-Ala-Gly-Lys-Arg-Gly (SEQ ID NO: 2)
<3> Val-Gly-Pro-Val-Thr-Glu-Glu-Val-Ser-Pro-Ala-Lys (SEQ ID NO: 3)
<4> Ser-Ala-Gly-Gln-Asn-Pro-Ala-Asp-Asp-Val (SEQ ID NO: 4)
<5> Gly-Thr-Pro (OH) -Gly-Ala-Gly-Gly-Ser-Arg (SEQ ID NO: 5)
<6> Gln-Gly-Pro-Gln-Gly-Glu-Leu (SEQ ID NO: 6)
Pro (OH) represents hydroxyproline.
(9)項1〜7のいずれか1項に記載のクラゲコラーゲンペプチド混合物、及び/または項8に記載のペプチドを含有する外用剤。
(9) An external preparation containing the jellyfish collagen peptide mixture according to any one of Items 1 to 7 and / or the peptide according to
(10)項1〜7のいずれか1項に記載のクラゲコラーゲンペプチド混合物、及び/または項8に記載のペプチドを含有する角化細胞賦活剤。
(10) A keratinocyte activator comprising the jellyfish collagen peptide mixture according to any one of Items 1 to 7 and / or the peptide according to
(11)項1〜7のいずれか1項に記載のクラゲコラーゲンペプチド混合物、及び/または項8に記載のペプチドを含有するインボルクリン産生促進剤。
(11) An involucrin production promoter containing the jellyfish collagen peptide mixture according to any one of Items 1 to 7 and / or the peptide according to
(12)項1〜7のいずれか1項に記載のクラゲコラーゲンペプチド混合物、及び/または項8に記載のペプチドを含有するトランスグルタミナーゼ産生促進剤。
(12) A transglutaminase production promoter containing the jellyfish collagen peptide mixture according to any one of items 1 to 7 and / or the peptide according to
(13)項1〜7のいずれか1項に記載のクラゲコラーゲンペプチド混合物、及び/または項8に記載のペプチドを含有する抗炎症剤。
(13) An anti-inflammatory agent comprising the jellyfish collagen peptide mixture according to any one of items 1 to 7 and / or the peptide according to
本発明により未利用資源のクラゲを有効活用することができ、クラゲコラーゲンペプチドの混合物を比較的安価に提供することができる。また、本発明の角化細胞賦活効果、インボルクリン産生促進効果、トランスグルタミナーゼ産生促進効果、抗炎症効果に優れたクラゲコラーゲンペプチドを外用剤として経皮投与することにより、角層の形成が促進され、角質のバリア機能を修復改善することができる。 According to the present invention, an unused resource jellyfish can be effectively used, and a mixture of jellyfish collagen peptides can be provided relatively inexpensively. In addition, keratinocyte activation effect, involculin production promotion effect, transglutaminase production promotion effect of the present invention, jellyfish collagen peptide excellent in anti-inflammatory effect is transdermally administered as an external preparation, the formation of the stratum corneum is promoted, The keratin barrier function can be repaired and improved.
本明細書において用いる「クラゲコラーゲンペプチド」なる用語はクラゲコラーゲン由来のアミノ酸配列を含むペプチドをいう。本明細書において、クラゲコラーゲンペプチドの混合物(クラゲコラーゲンペプチド混合物)をクラゲコラーゲンペプチドということが
あり、クラゲコラーゲン由来のアミノ酸配列情報に基づき合成によって得られたペプチドをクラゲコラーゲンペプチドということがある。
As used herein, the term “jellyfish collagen peptide” refers to a peptide comprising an amino acid sequence derived from jellyfish collagen. In the present specification, a mixture of jellyfish collagen peptides (jellyfish collagen peptide mixture) may be referred to as jellyfish collagen peptide, and a peptide obtained by synthesis based on amino acid sequence information derived from jellyfish collagen may be referred to as jellyfish collagen peptide.
本発明のクラゲコラーゲンペプチドの混合物は、クラゲコラーゲンの加水分解により得ることができる。一実施態様において、クラゲコラーゲンペプチドの混合物は下記アミノ酸配列のいずれかを含むクラゲコラーゲンペプチドを含有するものである。また、合成で得られた下記アミノ酸配列を含むペプチドを用いることも、合成によって得られた下記アミノ酸配列を含むペプチドと、クラゲコラーゲンを加水分解して得られたクラゲコラーゲンペプチドとの混合物を用いることもできる。 The mixture of jellyfish collagen peptides of the present invention can be obtained by hydrolysis of jellyfish collagen. In one embodiment, the mixture of jellyfish collagen peptides contains jellyfish collagen peptides comprising any of the following amino acid sequences: In addition, a peptide containing the following amino acid sequence obtained by synthesis may be used, or a mixture of a peptide containing the following amino acid sequence obtained by synthesis and jellyfish collagen peptide obtained by hydrolyzing jellyfish collagen may be used. You can also.
<1>Gly-Pro-Ala-Gly(配列番号1)
<2>Pro-Gly-Val-Lys-Gly-Glu-Val-Gly-Glu-Ala-Gly-Lys-Arg-Gly(配列番号2)
<3>Val-Gly-Pro-Val-Thr-Glu-Glu-Val-Ser-Pro-Ala-Lys(配列番号3)
<4>Ser-Ala-Gly-Gln-Asn-Pro-Ala-Asp-Asp-Val(配列番号4)
<5>Gly-Thr-Pro(OH)-Gly-Ala-Gly-Gly-Ser-Arg(配列番号5)
<6>Gln-Gly-Pro-Gln-Gly-Glu-Leu(配列番号6)
<1> Gly-Pro-Ala-Gly (SEQ ID NO: 1)
<2> Pro-Gly-Val-Lys-Gly-Glu-Val-Gly-Glu-Ala-Gly-Lys-Arg-Gly (SEQ ID NO: 2)
<3> Val-Gly-Pro-Val-Thr-Glu-Glu-Val-Ser-Pro-Ala-Lys (SEQ ID NO: 3)
<4> Ser-Ala-Gly-Gln-Asn-Pro-Ala-Asp-Asp-Val (SEQ ID NO: 4)
<5> Gly-Thr-Pro (OH) -Gly-Ala-Gly-Gly-Ser-Arg (SEQ ID NO: 5)
<6> Gln-Gly-Pro-Gln-Gly-Glu-Leu (SEQ ID NO: 6)
本発明のクラゲコラーゲンの加水分解には、ペプチド分解酵素または固体酸触媒を用いることができ、クラゲコラーゲンは、クラゲのタンパク質から得ることができる。 Peptide degrading enzymes or solid acid catalysts can be used for hydrolysis of the jellyfish collagen of the present invention, and jellyfish collagen can be obtained from jellyfish protein.
本発明で用いるクラゲの種類に特に制限はなく、例えば鉢虫網(Scyphozoa)、箱虫網(Cubozoa)、十文字クラゲ網(Staurozoa)及びヒドロ虫網(Hydrozoa)等に属するクラゲを用いることができ、具体的には、ミズクラゲ、アカクラゲ、ビゼンクラゲ、エチゼンクラゲ、エフィラクラゲ、ヒラタカムリクラゲ、クロカムリクラゲ、アマクサクラゲ、ヤナギクラゲ、ユウレイクラゲ、アマガサクラゲ、サムクラゲ、エビクラゲ、イボクラゲ、サカサクラゲ、ムラサキクラゲ、キタミズクラなどを用いることができる。これらのなかでも、資源の豊富さの観点から、ミズクラゲ、エチゼンクラゲを好ましく用いることができ、ミズクラゲを特に好ましく用いることができる。例えば、アミノ酸配列<1>〜<6>のいずれかを含むクラゲコラーゲンを本発明において好適に使用することができる。 There are no particular limitations on the type of jellyfish used in the present invention, and for example, jellyfish belonging to the Scyphozoa, Boxbo (Cubozoa), Cross jellyfish (Staurozoa), Hydrozoa, etc. can be used. Specific examples include moon jellyfish, red jellyfish, bizen jellyfish, Echizen jellyfish, Efila jellyfish, kingfisher jellyfish, black camphor jellyfish, Amakusa jellyfish, willow jellyfish, yellow jellyfish, Amaga jellyfish, samurai jellyfish, shrimp jellyfish, scorpion jellyfish, purple jellyfish, etc. Can be used. Among these, from the viewpoint of abundant resources, moon jellyfish and ethene jellyfish can be preferably used, and moon jellyfish can be particularly preferably used. For example, jellyfish collagen containing any one of the amino acid sequences <1> to <6> can be preferably used in the present invention.
まず、クラゲからタンパク質を抽出する方法について説明する。
クラゲからタンパク質を抽出する際、裁断機、ミンチ機及びカッター等を用いて破砕したものを用いることができ、クラゲを破砕することなく用いることもできる。クラゲまたはクラゲ破砕物を、4℃程度の低温下に1〜36時間置くことにより、あるいは、4℃程度の低温下のリン酸緩衝液又は0.2%程度の塩化ナトリウム溶液、または、水に1〜36時間浸漬することにより、タンパク質を含む水溶液が得られる。
First, a method for extracting protein from jellyfish will be described.
When extracting protein from a jellyfish, what was crushed using a cutting machine, a mincing machine, a cutter, etc. can be used, and it can also be used without crushing a jellyfish. Place jellyfish or crushed jellyfish in a low temperature of about 4 ° C. for 1 to 36 hours, or in a phosphate buffer solution of about 4 ° C. or a sodium chloride solution of about 0.2%, or water. By soaking for 1-36 hours, an aqueous solution containing protein is obtained.
タンパク質を含む水溶液は濾過し、さらに、塩化ナトリウムや硫酸アンモニウム等の無機塩を用いて塩析することにより、または、エタノールなどの低級アルコールで沈殿物とすることにより、不純物を除去することもできる。 The aqueous solution containing the protein can be filtered, and further impurities can be removed by salting out using an inorganic salt such as sodium chloride or ammonium sulfate, or by precipitation with a lower alcohol such as ethanol.
このようにして得られた粗タンパク質からクラゲコラーゲンを得る方法に特に制限はなく、例えば、タンパク質を含む水溶液を遠心分離して得られた固形物をエタノールなどの低級アルコールに分散させ、さらに遠心分離する方法が挙げられ、この操作によって、クラゲのコラーゲンを固形物として得ることができる。このクラゲコラーゲンを水で分散し、透析膜などで脱塩して精製したものを用いることもできる。 The method for obtaining jellyfish collagen from the crude protein thus obtained is not particularly limited. For example, a solid obtained by centrifuging an aqueous solution containing the protein is dispersed in a lower alcohol such as ethanol, and further centrifuged. By this operation, jellyfish collagen can be obtained as a solid. A product obtained by dispersing this jellyfish collagen with water and desalting it with a dialysis membrane or the like can also be used.
遠心分離で得られた前記固形物に水を加えて分散した後、さらに遠心分離し、その上澄み中のクラゲコラーゲンと沈殿したクラゲコラーゲンとを、それぞれ個別に使用することもできる。本明細書において、沈殿したクラゲコラーゲンについては、pH1〜4の酸性
溶液に透明に溶解することから「酸性可溶性コラーゲン」と称する。なお、この酸性可溶性コラーゲンは、pH4〜10の範囲では水に不溶であるが、pH10以上のアルカリ域では分散状態を取りうる。また、本明細書において、上澄み中のクラゲコラーゲンは、酸性可溶性コラーゲンに対して「中性可溶性コラーゲン」と称する。なお、この中性可溶性コラーゲンはpH域に関わらず、水に可溶のコラーゲンである。
Water can be added to the solid material obtained by centrifugation to disperse it, followed by further centrifugation, and the jellyfish collagen in the supernatant and the precipitated jellyfish collagen can be used individually. In the present specification, the precipitated jellyfish collagen is referred to as “acid-soluble collagen” because it is transparently dissolved in an acidic solution having a pH of 1 to 4. This acidic soluble collagen is insoluble in water in the range of pH 4 to 10, but can be dispersed in an alkaline region of pH 10 or higher. Moreover, in this specification, the jellyfish collagen in a supernatant is called "neutral soluble collagen" with respect to acidic soluble collagen. The neutral soluble collagen is soluble in water regardless of the pH range.
クラゲコラーゲンペプチドの作成においては、酸性可溶性コラーゲンより、中性可溶性コラーゲンを好ましく用いることができる。なお、酸性可溶性コラーゲンの割合は、キレート剤で予め金属成分を除去しておくことにより低減させることができる。 In producing a jellyfish collagen peptide, neutral soluble collagen can be preferably used rather than acidic soluble collagen. In addition, the ratio of acidic soluble collagen can be reduced by removing a metal component beforehand with a chelating agent.
(クラゲコラーゲンのペプチド分解酵素による加水分解)
本明細書において用いる「ペプチド分解酵素」なる用語は、タンパク質を分解してペプチドを生成する酵素をいう。分解により得られるペプチドの分子量は、150〜35,000Daであることが好ましく、250〜30,000Daであることがより好ましい。
(Hydrolysis of jellyfish collagen by peptide-degrading enzyme)
As used herein, the term “peptide degrading enzyme” refers to an enzyme that degrades a protein to produce a peptide. The molecular weight of the peptide obtained by decomposition is preferably 150 to 35,000 Da, and more preferably 250 to 30,000 Da.
クラゲコラーゲンの加水分解に用いるペプチド分解酵素に特に制限はないが、トリプシン、ペプシン、パパインからなる群より選ばれた少なくとも1種であることが好ましい。 The peptide degrading enzyme used for hydrolysis of jellyfish collagen is not particularly limited, but is preferably at least one selected from the group consisting of trypsin, pepsin, and papain.
このうちトリプシンは、分子量約23000のプロテアーゼであり、不活性型前駆体の
トリプシノーゲンとして膵臓から分泌され、自己限定分解によって活性型に変化したものである。生物実験では、アルギニン、リシンのC末端側を特異的に加水分解することを利用してタンパク質の構造解析に利用するほか、付着性細胞の継代などに用いられる。トリプシンの使用量は、基質となるクラゲコラーゲンの0.0001〜5質量%であることが好ましく、0.001〜2質量%であることがより好ましく、0.01〜1質量%であることがさらに好ましい。トリプシンによる処理条件に特に制限はないが、pH7〜9、30〜40℃であることが好ましい。
Among them, trypsin is a protease having a molecular weight of about 23,000, secreted from the pancreas as an inactive precursor trypsinogen, and changed to an active form by self-limited degradation. In biological experiments, it is used not only for structural analysis of proteins by specifically hydrolyzing the C-terminal side of arginine and lysine, but also for passage of adherent cells. The amount of trypsin used is preferably 0.0001 to 5% by mass, more preferably 0.001 to 2% by mass, and 0.01 to 1% by mass of the jellyfish collagen as a substrate. Further preferred. Although there is no restriction | limiting in particular in the processing conditions by a trypsin, It is preferable that they are pH 7-9 and 30-40 degreeC.
ペプシンは、分子量約35000のプロテアーゼの一種であり、脊椎動物の胃液中に分泌された前駆体ペプシノーゲンが、塩酸または既存のペプシンの作用によりペプシンに変化する。ペプシンの使用量は、基質となるクラゲコラーゲンの0.0001〜5質量%であることが好ましく、0.001〜2質量%であることがより好ましく、0.01〜1質量%であることがさらに好ましい。ペプシンによる処理条件に特に制限はないが、pH1〜4、30〜40℃であることが好ましい。 Pepsin is a kind of protease having a molecular weight of about 35,000, and the precursor pepsinogen secreted in the vertebrate gastric fluid is converted into pepsin by the action of hydrochloric acid or existing pepsin. The amount of pepsin used is preferably 0.0001 to 5% by mass, more preferably 0.001 to 2% by mass, and 0.01 to 1% by mass of the jellyfish collagen as a substrate. Further preferred. Although there is no restriction | limiting in particular in the processing conditions by pepsin, It is preferable that they are pH 1-4 and 30-40 degreeC.
パパインは、パパイアの果肉に含まれる分子量約23000のプロテアーゼであり、消化剤やビールの清澄剤などに用いられる酵素である。パパインの使用量は、基質となるクラゲコラーゲンの0.0001〜5質量%であることが好ましく、0.001〜2質量%であることがより好ましく、0.01〜1質量%であることがさらに好ましい。パパインによる処理条件に特に制限はないが、pH4〜10、20〜80℃であることが好ましい。 Papain is a protease having a molecular weight of about 23,000 contained in papaya pulp, and is an enzyme used for digestives, beer clarifiers, and the like. The amount of papain used is preferably 0.0001 to 5% by mass, more preferably 0.001 to 2% by mass, and 0.01 to 1% by mass of jellyfish collagen as a substrate. Further preferred. Although there is no restriction | limiting in particular in the process conditions by a papain, It is preferable that it is pH 4-10, 20-80 degreeC.
これらのペプチド分解酵素(トリプシン、ペプシン、パパイン)は、1種を用いることができ、2種以上を組み合わせて用いることもできるが、2種以上のペプチド分解酵素をもちいるのが好ましい。 These peptide degrading enzymes (trypsin, pepsin, papain) can be used alone or in combination of two or more, but it is preferable to use two or more peptidases.
クラゲコラーゲンを2種以上のペプチド分解酵素で加水分解する場合において、クラゲコラーゲンが酸性可溶性コラーゲン、または、酸性可溶性コラーゲンと中性可溶性コラーゲンとの混合物である場合には、まずペプシンで加水分解することが好ましい。酸性条件で分解活性のあるペプシンで加水分解することにより、中性のpH域でも可溶のコラーゲンペプチドを得ることができ、トリプシンおよび/またはパパインでさらに加水分解することが可能となる。このペプシンによる加水分解の後、さらにトリプシンおよび/または
パパインで加水分解する方法は、中性可溶性コラーゲンの加水分解にも用いることができる。例えば、ペプシンとトリプシン、ペプシンとパパインとトリプシンの組み合わせを本発明において好適に使用することができる。
When jellyfish collagen is hydrolyzed with two or more types of peptide degrading enzymes, if jellyfish collagen is acidic soluble collagen or a mixture of acidic soluble collagen and neutral soluble collagen, first hydrolyze with pepsin. Is preferred. By hydrolyzing with pepsin that is active under acidic conditions, a collagen peptide that is soluble even in a neutral pH range can be obtained, and further hydrolyzed with trypsin and / or papain. After the hydrolysis with pepsin, the method of further hydrolyzing with trypsin and / or papain can also be used for the hydrolysis of neutral soluble collagen. For example, a combination of pepsin and trypsin, pepsin, papain and trypsin can be preferably used in the present invention.
(クラゲコラーゲンの固体酸触媒による加水分解)
クラゲコラーゲンペプチドの混合物は、クラゲコラーゲンを固体酸触媒で加水分解して得ることもできる。固体酸触媒による加水分解は、水の存在下、且つ加熱下で、固体酸触媒とクラゲコラーゲンとを接触させて、クラゲコラーゲンを加水分解する方法である。加水分解効率の観点から、クラゲコラーゲンは中性可溶性コラーゲンであることが好ましい。
(Jellyfish collagen hydrolysis by solid acid catalyst)
The mixture of jellyfish collagen peptides can also be obtained by hydrolyzing jellyfish collagen with a solid acid catalyst. The hydrolysis with a solid acid catalyst is a method of hydrolyzing jellyfish collagen by bringing the solid acid catalyst into contact with jellyfish collagen in the presence of water and under heating. From the viewpoint of hydrolysis efficiency, the jellyfish collagen is preferably neutral soluble collagen.
本発明おいて、酸として機能し得る固体触媒を特に制限なく固体酸触媒として用いることができるが、加水分解効率の観点から、陽イオン交換体、ゼオライトおよび珪藻土からなる群から選ばれる少なくとも一種であることが好ましく、陽イオン交換体であることがより好ましい。これらの固体酸触媒は、1種のみを用いることも、2種以上を組み合わせて用いることもできる。 In the present invention, a solid catalyst that can function as an acid can be used as a solid acid catalyst without any particular limitation, but from the viewpoint of hydrolysis efficiency, it is at least one selected from the group consisting of a cation exchanger, zeolite, and diatomaceous earth. Preferably, it is a cation exchanger. These solid acid catalysts can be used alone or in combination of two or more.
陽イオン交換体は、スルホン基、カルボキシル基の少なくとも1種を有する樹脂であることが好ましく、スルホン基、カルボキシル基は、それぞれスルホプロピル基、カルボキシメチル基であってもよい。陽イオン交換体のカウンターイオンがプロトン以外である場合、プロトン型に置換した後に使用することが好ましい。特に好ましい陽イオン交換体は、スルホプロピル基などの強酸性陽イオン交換基を有するスルホン酸型陽イオン交換体であり、陽イオン交換樹脂、陽イオン交換膜を好ましい形態としてあげることができる。スルホン酸型陽イオン交換樹脂の具体例としては、東ソー株式会社製TOYOPEARL SP−650C、SP−550C等のように親水性ビニルポリマーを基材として含むものや、ナフィオン(登録商標)等のようにパーフルオロスルホン酸を含むポリテトラフルオロエチレン共重合体を挙げることができる。 The cation exchanger is preferably a resin having at least one of a sulfone group and a carboxyl group, and the sulfone group and the carboxyl group may be a sulfopropyl group and a carboxymethyl group, respectively. When the counter ion of the cation exchanger is other than proton, it is preferable to use it after substitution with the proton type. A particularly preferred cation exchanger is a sulfonic acid type cation exchanger having a strongly acidic cation exchange group such as a sulfopropyl group, and a cation exchange resin and a cation exchange membrane can be mentioned as preferred forms. Specific examples of the sulfonic acid type cation exchange resin include those containing a hydrophilic vinyl polymer as a base material such as TOYOPEARL SP-650C and SP-550C manufactured by Tosoh Corporation, and Nafion (registered trademark). A polytetrafluoroethylene copolymer containing perfluorosulfonic acid can be mentioned.
ゼオライトとしては、一般にゼオライト触媒として利用されているゼオライトを用いることができ、中でも、東ソー株式会社製ゼオラム(登録商標)を好ましく用いることができる。
珪藻土としては、例えば和光純薬工業株式会社製けいそう土(顆粒状)等が挙げられる。
As zeolite, zeolite which is generally used as a zeolite catalyst can be used, and among them, Zeorum (registered trademark) manufactured by Tosoh Corporation can be preferably used.
Examples of diatomaceous earth include diatomaceous earth (granular) manufactured by Wako Pure Chemical Industries, Ltd.
前記固体酸触媒の形状に制限はなく、粒状、粉末状等の任意の形態を取り得る。粒状または粉末状であれば、加水分解させるべきクラゲコラーゲンを含む水溶液中に固体酸触媒を混合するバッチ法に使用することもでき、固体酸触媒を充填したカラムへクラゲコラーゲン水溶液を連続送液する連続法に使用することもできる。また、固体酸触媒からなる膜や粒状または粉末状の固体酸触媒を固定化した膜に、クラゲコラーゲン水溶液を通過させることもできる。 There is no restriction | limiting in the shape of the said solid acid catalyst, Arbitrary forms, such as a granular form and a powder form, can be taken. If it is granular or powdery, it can be used in a batch method in which a solid acid catalyst is mixed in an aqueous solution containing jellyfish collagen to be hydrolyzed, and the jellyfish collagen aqueous solution is continuously fed to a column packed with the solid acid catalyst. It can also be used in a continuous process. Further, the jellyfish collagen aqueous solution can be passed through a membrane made of a solid acid catalyst or a membrane on which a granular or powdery solid acid catalyst is immobilized.
前記固体酸触媒としては、例えば平均粒子径が2μm〜2mm程度、イオン交換容量が0.01〜1eq/L程度のものを使用することができる。本発明におけるクラゲコラーゲンの加水分解は、固体酸触媒上の酸点の作用により進行するものと考えられる。従って、クラゲコラーゲン吸着能が高い固体酸触媒を使用することが好ましく、クラゲコラーゲン吸着量が5〜150g/Lの固体酸触媒を使用することが好ましい。例えば、前述の東ソー株式会社製TOYOPEARL SP−650Cのクラゲコラーゲン吸着量は35〜55g/L程度、TOYOPEARL SP−550Cのクラゲコラーゲン吸着量は80〜120g/L程度である。 As the solid acid catalyst, for example, one having an average particle diameter of about 2 μm to 2 mm and an ion exchange capacity of about 0.01 to 1 eq / L can be used. The hydrolysis of jellyfish collagen in the present invention is considered to proceed by the action of acid sites on the solid acid catalyst. Therefore, it is preferable to use a solid acid catalyst having a high jellyfish collagen adsorption capacity, and it is preferable to use a solid acid catalyst having a jellyfish collagen adsorption amount of 5 to 150 g / L. For example, the above-mentioned TOYOPEARL SP-650C manufactured by Tosoh Corporation has a jellyfish collagen adsorption amount of about 35 to 55 g / L, and the TOYOPEARL SP-550C has a jellyfish collagen adsorption amount of about 80 to 120 g / L.
前記固体酸触媒としては、多孔質体であることがより好ましい。比表面積が増大するほど吸着性が向上するとの観点から、細孔サイズが小さい多孔質体であることが好ましいが、細孔サイズより大きなクラゲコラーゲンの細孔内での加水分解が困難となるため、クラゲコラーゲンの加水分解に適したサイズの細孔を有する固体酸触媒を選択することが好ましい。固体酸触媒として用いる多孔質体の好ましい細孔の径は、0.01〜0.75μmであり、より好ましくは、0.05〜0.6μmである。 The solid acid catalyst is more preferably a porous body. From the viewpoint of improving the adsorptivity as the specific surface area increases, it is preferable that the porous body has a small pore size, but hydrolysis of jellyfish collagen larger than the pore size in the pores becomes difficult. It is preferable to select a solid acid catalyst having pores of a size suitable for hydrolysis of jellyfish collagen. The preferable pore diameter of the porous body used as the solid acid catalyst is 0.01 to 0.75 μm, and more preferably 0.05 to 0.6 μm.
固体酸触媒によるクラゲコラーゲンの加水分解は、水存在下かつ加熱下で固体酸触媒とクラゲコラーゲンとを接触させることにより行われる。加熱なしでは加水分解反応を良好に進行させることが困難である。加熱温度としては80〜160℃程度、処理時間は5分〜40時間程度であることが好ましい。クラゲコラーゲンの分解はクラゲコラーゲンペプチドまでの分解に留めることが重要であるが、高温で長時間処理した場合、クラゲコラーゲンがアミノ酸にまで加水分解されるおそれがあるため、処理温度が高温であるほど、処理時間を短時間とするのが好ましい。より好ましい処理条件は、80〜120℃で5分〜20時間であり、さらに好ましくは、80〜120℃で5分〜5時間であり、より好ましくは90〜110℃で5分〜2時間である(固体酸触媒については例えば国際公開第2010/058590号も参照のこと)。 Hydrolysis of jellyfish collagen with a solid acid catalyst is carried out by contacting the solid acid catalyst with jellyfish collagen in the presence of water and under heating. Without heating, it is difficult to proceed the hydrolysis reaction well. The heating temperature is preferably about 80 to 160 ° C., and the treatment time is preferably about 5 minutes to 40 hours. It is important that the degradation of jellyfish collagen is limited to the degradation of jellyfish collagen peptide, but when treated at high temperature for a long time, jellyfish collagen may be hydrolyzed to amino acids. The processing time is preferably short. More preferable treatment conditions are 80 to 120 ° C. for 5 minutes to 20 hours, more preferably 80 to 120 ° C. for 5 minutes to 5 hours, more preferably 90 to 110 ° C. for 5 minutes to 2 hours. Yes (see also for example WO 2010/058590 for solid acid catalysts).
ペプチド分解酵素又は固体酸触媒を用いた加水分解によって得られたこれらのクラゲコラーゲンペプチド混合物は、加水分解していないクラゲコラーゲンと比較して増加した角化細胞賦活活性、インボルクリン産生促進活性、トランスグルタミナーゼ産生促進活性及び/または抗炎症活性を示すことができる。 These jellyfish collagen peptide mixtures obtained by hydrolysis using a peptide-degrading enzyme or a solid acid catalyst have increased keratinocyte activation activity, involucrin production promoting activity, transglutaminase compared to jellyfish collagen not hydrolyzed It can exhibit production promoting activity and / or anti-inflammatory activity.
本発明においては、アミノ酸配列<1>〜<6>のいずれかのアミノ酸配列を含むペプチドを合成して得ることもできる。前記アミノ酸配列を含むペプチドの合成方法に特に制限はなく、例えば、C末端アミノ酸をポリスチレンからなる固相に固定し、これに保護アミノ酸を結合させることによってアミノ基を伸長することができ、アミノ酸保護には、Fmoc(Fluorenyl-MethOxy-Carbonyl)基やBoc(tert-ButOxy- Carbonyl)基を用いることができる。固相のアミノ基と保護アミノ酸との反応終了後、固相を洗浄し、未反応の保護アミノ酸を除去することが好ましい。その後、固相に結合しているアミノ酸の末端の保護基を除去(脱保護)することにより、次の反応点となるアミノ基が得られる。使用する保護アミノ酸を順次変更することで、目的のアミノ酸配列を含むペプチドを得ることができる。本発明のペプチドは、加水分解していないクラゲコラーゲンと比較して、例えば1.2倍、好ましくは、1.5倍、より好ましくは1.8倍、さらに好ましくは2倍増加した角化細胞賦活活性、インボルクリン産生促進活性、トランスグルタミナーゼ産生促進活性及び/又は抗炎症活性を示す。アミノ酸配列<1>〜<6>のいずれかを含むペプチドは、アミノ酸配列<1>〜<6>のいずれかからなるペプチドであってもよい。 In the present invention, a peptide containing any one of the amino acid sequences <1> to <6> can be synthesized. There is no particular limitation on the method for synthesizing the peptide containing the amino acid sequence. For example, the amino group can be extended by fixing the C-terminal amino acid to a solid phase made of polystyrene and bonding a protected amino acid thereto, thereby protecting the amino acid. For example, an Fmoc (Fluorenyl-MethOxy-Carbonyl) group or a Boc (tert-ButOxy-Carbonyl) group can be used. After completion of the reaction between the amino group of the solid phase and the protected amino acid, the solid phase is preferably washed to remove the unreacted protected amino acid. Then, the amino group used as the next reaction point is obtained by removing (deprotecting) the protective group at the terminal of the amino acid bonded to the solid phase. A peptide containing the target amino acid sequence can be obtained by sequentially changing the protected amino acid to be used. The peptide of the present invention has a keratinocyte increased by, for example, 1.2 times, preferably 1.5 times, more preferably 1.8 times, and even more preferably 2 times compared to non-hydrolyzed jellyfish collagen. It exhibits activation activity, involucrin production promoting activity, transglutaminase production promoting activity and / or anti-inflammatory activity. The peptide comprising any one of the amino acid sequences <1> to <6> may be a peptide consisting of any one of the amino acid sequences <1> to <6>.
本発明の細胞賦活効果、インボルクリン産生促進効果、トランスグルタミナーゼ産生促進効果、抗炎症効果に優れたクラゲコラーゲンペプチドは、皮膚外用剤、化粧品、浴用剤などの外用剤の形態で経皮投与することができる。経皮投与の観点から、クラゲコラーゲンペプチドの分子量は、150〜35,000Daであることが好ましく、250〜30,000Daであることがより好ましい。 The jellyfish collagen peptide excellent in cell activation effect, involucrin production promotion effect, transglutaminase production promotion effect and anti-inflammatory effect of the present invention can be transdermally administered in the form of an external preparation such as an external preparation for skin, cosmetics or bath preparation. it can. From the viewpoint of transdermal administration, the molecular weight of the jellyfish collagen peptide is preferably 150 to 35,000 Da, and more preferably 250 to 30,000 Da.
本発明のクラゲコラーゲンペプチドの混合物を、外用剤として、皮膚外用剤または化粧品に製剤するときの剤型に特に制限はなく、ペースト剤、クリーム、ジェル、軟膏、ローション、乳液、パック、パウダー、パップ剤とすることができ、ウエットティッシュなどの紙製品に含浸して用いることもできる。皮膚外用薬、化粧品に配合するクラゲコラーゲンペプチドの量に特に制限はないが、皮膚外用剤中、化粧品中に0.0005〜50質量%であることが好ましい。本発明のクラゲコラーゲンペプチドを配合した皮膚外用剤、化
粧品の使用量にも特に制限はないが、クラゲコラーゲンペプチド量で成人1日当たり0.1〜1000mgとなる量を、1〜数回に分けて用いることが好ましい。
There is no particular limitation on the dosage form when the mixture of the jellyfish collagen peptide of the present invention is formulated as an external preparation into an external preparation for skin or cosmetics. Paste, cream, gel, ointment, lotion, emulsion, pack, powder, papp It can also be used as an agent, and can also be used by impregnating paper products such as wet tissue. Although there is no restriction | limiting in particular in the quantity of the jellyfish collagen peptide mix | blended with a skin external preparation and cosmetics, It is preferable that it is 0.0005-50 mass% in skin external preparations and cosmetics. Although there is no restriction | limiting in particular in the usage-amount of the skin external preparation and cosmetics which mix | blended the jellyfish collagen peptide of this invention, The quantity which becomes 0.1-1000 mg per day for an adult in a jellyfish collagen peptide is divided into 1 to several times. It is preferable to use it.
本発明のクラゲコラーゲンペプチド混合物を、外用剤として浴用剤に製剤する場合の剤型にも制限はなく、粉末、顆粒状などの固形製剤、乳液、ペースト状などの液体製剤等として用いることができる。浴用剤に配合可能なクラゲコラーゲンペプチドの量に特に制限はないが、浴用剤中に0.0005〜50質量%であることが好ましい。 There is no limitation on the dosage form when the jellyfish collagen peptide mixture of the present invention is formulated into a bath preparation as an external preparation, and it can be used as a solid preparation such as powder or granule, a liquid preparation such as emulsion or paste. . Although there is no restriction | limiting in particular in the quantity of the jellyfish collagen peptide which can be mix | blended with a bath agent, It is preferable that it is 0.0005-50 mass% in a bath agent.
本発明の皮膚外用剤、化粧品および浴用剤などの外用剤には、本発明のクラゲコラーゲンペプチドのほかに、皮膚外用剤、化粧品又は浴用剤で使用される公知の機能性成分、例えば、グリセリン、ブチレングリコール、尿素、アミノ酸類などの保湿剤;スクワラン、マカデミアナッツ油、ホホバ油などのエモリエント剤;ビタミンE類、トウガラシチンキなどの血行促進剤;ジブチルヒドロキシトルエン(BHT)、ジブチルヒドロキシアニソール(BHA)、酢酸トコフェロール、アスコルビン酸などの抗酸化剤;グリチルリチン、アラントインなどの抗炎症剤;ヒノキチオール、塩化ベンザルコニウム、クロルヘキシジン塩、パラヒドロキシ安息香酸エステルなどの抗菌剤;アスコルビン酸、アルブチンなどの美白剤;スーパーオキシドジスムターゼ(SOD)等の過酸化物抑制剤、など種々の公知物質等を配合することができる。また、イチョウエキス、胎盤抽出物、乳酸菌培養抽出物などの植物・動物・微生物由来の各種抽出物などを添加することができる。 In addition to the jellyfish collagen peptide of the present invention, the external preparations such as skin external preparations, cosmetics and bath preparations of the present invention include known functional ingredients used in skin external preparations, cosmetics or bath preparations, such as glycerin, Moisturizers such as butylene glycol, urea and amino acids; emollients such as squalane, macadamia nut oil and jojoba oil; blood circulation promoters such as vitamin E and pepper tincture; dibutylhydroxytoluene (BHT), dibutylhydroxyanisole (BHA), Anti-inflammatory agents such as tocopherol acetate and ascorbic acid; anti-inflammatory agents such as glycyrrhizin and allantoin; antibacterial agents such as hinokitiol, benzalkonium chloride, chlorhexidine salt and parahydroxybenzoate; whitening agents such as ascorbic acid and arbutin; super Oxide Sumutaze (SOD) peroxide inhibitors such as, various known materials such as such can be blended. Moreover, various extracts derived from plants, animals, and microorganisms such as ginkgo biloba extract, placenta extract, and lactic acid bacteria culture extract can be added.
また、前記皮膚外用剤、化粧品、浴用剤などの外用剤には、その剤型化のために界面活性剤や油脂類などの基剤成分を配合することができ、必要に応じて増粘剤、防腐剤、等張化剤、酸化防止剤、紫外線吸収剤、キレート剤、香料、着色料など種々の添加剤を併用することもできる。 In addition, in the external preparations such as the above-mentioned external preparations for skin, cosmetics, bath preparations, base components such as surfactants and fats and oils can be blended for the formulation, and thickeners are added as necessary. Various additives such as preservatives, tonicity agents, antioxidants, ultraviolet absorbers, chelating agents, fragrances, and coloring agents can be used in combination.
使用可能な界面活性剤に制限はなく、高級アルキルアミンのアルキレンオキサイド付加物、高級脂肪酸アミドのアルキレンオキサイド付加物、多価アルコールの脂肪酸エステル、硬化ひまし油のアルキレンオキサイド付加物、ポリエチレングリコールソルビタンアルキルエステル、ステロール等のアルキレンオキサイド付加物等の非イオン界面活性剤、アルキル硫酸ナトリウム、アルキロイルメチルタウリンナトリウム、α−オレフィンスルホン酸ナトリウム、ポリオキシアルキレンアルキルエーテル硫酸ナトリウム等の陰イオン界面活性剤、塩化アルキルピリジニウム、塩化ジステアリルジメチルアンモニウム等の陽イオン界面活性剤、アルキルアミノプロピオン酸ナトリウム、アルキルポリアミノエチルグリシン等の両イオン性界面活性剤を用いることができる。これらの界面活性剤は1種を用いることができ、2種以上を同時に用いることもできる。 There is no limitation on the surfactant that can be used, alkylene oxide adduct of higher alkylamine, alkylene oxide adduct of higher fatty acid amide, fatty acid ester of polyhydric alcohol, alkylene oxide adduct of hardened castor oil, polyethylene glycol sorbitan alkyl ester, Nonionic surfactants such as alkylene oxide adducts such as sterols, anionic surfactants such as sodium alkyl sulfate, sodium alkyloxyl taurate, sodium α-olefin sulfonate, sodium polyoxyalkylene alkyl ether sulfate, alkylpyridinium chloride , Cationic surfactants such as distearyldimethylammonium chloride, amphoteric surfactants such as sodium alkylaminopropionate and alkylpolyaminoethylglycine It can be used. These surfactants can be used alone or in combination of two or more.
前記基剤として用いる成分に特に制限はなく、オリーブ油、ツバキ油、ホホバ油、アボガド油、マカデミアナッツ油、杏仁油、スクワラン、スクワレン、馬油などの油脂類を用いることができる。 There is no restriction | limiting in particular in the component used as the said base, Oils and fats, such as olive oil, camellia oil, jojoba oil, avocado oil, macadamia nut oil, apricot oil, squalane, squalene, horse oil, can be used.
前記増粘剤として用いる成分に特に制限はないが、水溶性高分子が好ましく、例えば、ポリビニルアルコール、ポリアクリルアミド、ポリエチレングリコール、及びこれらの誘導体;ヒドロキシアルキルセルロースなどのセルロース類及びその誘導体;デキストラン、ゼラチン、アラビアガム、トラガントガムなどのガム類;カルボキシビニルポリマーなどを用いることができる。 The component used as the thickener is not particularly limited, but a water-soluble polymer is preferable, for example, polyvinyl alcohol, polyacrylamide, polyethylene glycol, and derivatives thereof; celluloses such as hydroxyalkyl cellulose and derivatives thereof; dextran, Gums such as gelatin, gum arabic, and tragacanth; carboxyvinyl polymer and the like can be used.
前記防腐剤として用いる成分に特に制限はなく、例えば、パラヒドロキシ安息香酸エステル、塩化アルキルピリジニウム、塩化ベンザルコニウム、クロルヘキシジン塩、ヒノキチオールなどを用いることができる。 There is no restriction | limiting in particular in the component used as said preservative, For example, parahydroxybenzoic acid ester, an alkyl pyridinium chloride, benzalkonium chloride, a chlorhexidine salt, hinokitiol etc. can be used.
前記等張化剤として用いる成分に特に制限はなく、例えば、塩化ナトリウム、塩化カリウム、塩化カルシウムなどの無機塩類を用いることができる。 There is no restriction | limiting in particular in the component used as said tonicity agent, For example, inorganic salts, such as sodium chloride, potassium chloride, and calcium chloride, can be used.
前記紫外線吸収剤として用いる成分に特に制限はなく、例えば、パラアミノ安息香酸、ベンゾフェノン系紫外線吸収剤、ベンゾトリアゾール系紫外線吸収剤などを用いることができきる。 There is no restriction | limiting in particular in the component used as the said ultraviolet absorber, For example, a paraamino benzoic acid, a benzophenone series ultraviolet absorber, a benzotriazole type ultraviolet absorber etc. can be used.
使用可能なキレート剤に特に制限はなく、例えば、エチレンジアミン四酢酸、フィチン酸、クエン酸及びこれらの水溶性塩などを挙げることができる。 There is no restriction | limiting in particular in the chelating agent which can be used, For example, ethylenediaminetetraacetic acid, phytic acid, a citric acid, and these water-soluble salts can be mentioned.
以下、実施例を挙げて本発明をさらに具体的に説明するが、本発明を限定するものではない。
1.クラゲコラーゲンの調製
蒸留水で洗浄したミズクラゲ(採取地:東京湾)の個体計1Kgを、5mm〜1cmの角状断片に切断した。これを、4℃下で24時間撹拌してタンパク質を含む溶液を得た。これをガーゼでろ過して、濾液に等容量の局法エタノール(A)を加え、撹拌して沈殿物を得た。この沈殿物に再度局法エタノール(A)と同量の局方エタノールを加え、遠心分離(10000×G)を行った。得られた固形物を蒸留水に分散し、分画分子量(MWCO):14000の透析膜を用いて脱塩処理を行った。これを遠心分離(10000×G)して、上澄み層と沈殿層とに分別し中性可溶性コラーゲン(上澄み)と、酸性可溶性コラーゲン(沈殿物)を得た。
Hereinafter, the present invention will be described more specifically with reference to examples, but the present invention is not limited thereto.
1. Preparation of Jellyfish Collagen A 1 Kg population of moon jellyfish (collected from: Tokyo Bay) washed with distilled water was cut into 5 mm to 1 cm square pieces. This was stirred at 4 ° C. for 24 hours to obtain a protein-containing solution. This was filtered with gauze, and an equal volume of local ethanol (A) was added to the filtrate and stirred to obtain a precipitate. The same amount of local ethanol as local ethanol (A) was again added to the precipitate, followed by centrifugation (10000 × G). The obtained solid was dispersed in distilled water and subjected to desalting using a dialysis membrane having a molecular weight cut-off (MWCO) of 14,000. This was centrifuged (10000 × G) and separated into a supernatant layer and a precipitate layer to obtain neutral soluble collagen (supernatant) and acidic soluble collagen (precipitate).
2.抽出された中性可溶性コラーゲンのアミノ酸分析
アミノ酸の分析では、6−アミノキノリル−N−ヒドロキシスクシンイミジルカルバメート(AQC)を蛍光誘導体化試薬として用いた、
凍結乾燥した中性可溶性コラーゲンの10μgを水10μLに溶解し、ガラスチューブ(6×32mm,CHROMACOL 03−CVG)内で乾固させた。
2. Amino acid analysis of extracted neutral soluble collagen In the amino acid analysis, 6-aminoquinolyl-N-hydroxysuccinimidyl carbamate (AQC) was used as a fluorescent derivatization reagent,
10 μg of lyophilized neutral soluble collagen was dissolved in 10 μL of water and dried in a glass tube (6 × 32 mm, CHROMACOL 03-CVG).
ガラスバイアル(WHEATON 225289)内に、フェノール結晶一片を加えた6N塩酸200μLと、前記ガラスチューブを入れ、ロータリー真空ポンプで減圧の上、ガラスバイアルを封印した。このガラスバイアルをアルミブロックヒーターにセットし、110℃にて20時間加熱して、中性可溶性コラーゲンをアミノ酸に加水分解した。 In a glass vial (WHEATON 225289), 200 μL of 6N hydrochloric acid added with a piece of phenol crystal and the glass tube were put, and the glass vial was sealed with a rotary vacuum pump under reduced pressure. This glass vial was set in an aluminum block heater and heated at 110 ° C. for 20 hours to hydrolyze neutral soluble collagen into amino acids.
前記中性可溶性コラーゲンの加水分解物(アミノ酸)に、20mM塩酸10μL、0.2Mホウ酸緩衝液(pH8.8)30μL、AQC溶液(AQC3mg/mlのアセトニトリル溶液)10μLを加えて、55℃にて10分間加熱して、コラーゲンの加水分解物(アミノ酸)をアミノ酸蛍光誘導体とし、高速液体クロマトグラフ(HPLC)で分離した。
To the hydrolyzate (amino acid) of neutral soluble collagen, 10 μL of 20 mM hydrochloric acid, 30 μL of 0.2 M borate buffer (pH 8.8) and 10 μL of AQC solution (
a)HPLC装置:Agilent社の1200シリーズ(真空デガッサーG1379B、バイナリーポンプG1312B、オートサンプラーG1329B、カラム恒温槽G1316B、ダイオードアレイ検出器G1315C、蛍光検出器G1321Aを含む)
b)カラム: Inertsustain C18HP(3.0×250mm,3μm)、GLサイエンス社製
c)移動相
A液:95%5mMテトラブチルアンモニウムブロミド−30mMリン酸緩衝液(pH7.3)/5%アセトニトリル
B液:50%30mMリン酸緩衝液(pH7.3)/50%アセトニトリル
A液98%、B液2%から開始し、3.75分後のB液が7.3%に、さらに、50分後
のB液が72.3%となるように濃度勾配を設けた。
d)流速:0.4ml/分
e)温度:50℃
f)蛍光励起波長(Ex):250nm
g)モニター波長(Em):395nm
ピアス社製Amino Acid Standard H(2.5μmol/ml)の10pmol/μL溶液を標準アミノ酸溶液として、アミノ酸を定量した。結果を次表に示す。
a) HPLC apparatus: Agilent 1200 series (including vacuum degasser G1379B, binary pump G1312B, autosampler G1329B, column thermostat G1316B, diode array detector G1315C, and fluorescence detector G1321A)
b) Column: Inertsustain C18HP (3.0 × 250 mm, 3 μm), manufactured by GL Sciences Inc. c) Mobile phase A solution: 95% 5 mM tetrabutylammonium bromide-30 mM phosphate buffer (pH 7.3) / 5% acetonitrile B Solution: 50% 30 mM phosphate buffer solution (pH 7.3) / 50% acetonitrile Starting from solution A 98%,
d) Flow rate: 0.4 ml / min e) Temperature: 50 ° C
f) Fluorescence excitation wavelength (Ex): 250 nm
g) Monitor wavelength (Em): 395 nm
Amino acid was quantified using Pierce's Amino Acid Standard H (2.5 μmol / ml) in 10 pmol / μL as a standard amino acid solution. The results are shown in the following table.
クラゲコラーゲンは、30%以上のGlyを含有するものであった。
*Lys(OH)、3Pro(OH)、4Pro(OH)はそれぞれ、ヒドロキシル基含有アミノ酸を示す。
Jellyfish collagen contained 30% or more Gly.
* Lys (OH), 3Pro (OH), and 4Pro (OH) each represent a hydroxyl group-containing amino acid.
3.抽出されたクラゲコラーゲンの金属分の測定
凍結乾燥した中性可溶性コラーゲンを0.1g精秤して、硝酸10mlを加え、マイクロ波(MARS5 CEM社製)でこれを湿式分解した。分解液を50mlにメスアップし、発光分光分析計(PerkinElmer製Optima5300DV)で金属分を測定した。酸性可溶性コラーゲンに対しても同様の操作を行った。
3. Measurement of metal content of extracted jellyfish collagen 0.1 g of lyophilized neutral soluble collagen was precisely weighed, 10 ml of nitric acid was added, and this was wet-decomposed with microwaves (made by MARS5 CEM). The decomposition solution was made up to 50 ml, and the metal content was measured with an emission spectrophotometer (Optima 5300 DV manufactured by PerkinElmer). The same operation was performed on acidic soluble collagen.
4.クラゲコラーゲンペプチドの作成と分子量分布、質量分析およびアミノ酸配列の解析
以下の実施例におけるクラゲコラーゲンペプチド混合物の分子量分布は、ゲルろ過クロマトグラフィー(カラム:TSKgel Super SW2000、東ソー)を用いて測定した。
溶媒:6Mグアニジン塩酸/10mMリン酸緩衝液(pH6)
流速:0.15ml/分
測定波長:215nm
4). Preparation of Jellyfish Collagen Peptide, Molecular Weight Distribution, Mass Spectrometry, and Analysis of Amino Acid Sequence The molecular weight distribution of the jellyfish collagen peptide mixture in the following examples was measured using gel filtration chromatography (column: TSKgel Super SW2000, Tosoh).
Solvent: 6M guanidine hydrochloride / 10 mM phosphate buffer (pH 6)
Flow rate: 0.15 ml / min Measurement wavelength: 215 nm
また、得られたクラゲコラーゲンペプチド混合物を逆相クロマトグラフィーで分離し、質量分析(Ultraflex TOF/TOF、BRUKER DALTONICS)およびアミノ酸配列解析(PROCISE 494cLC プロテインシークエンサー、Applied Biosystems)を行った。 Moreover, the obtained jellyfish collagen peptide mixture was isolate | separated by the reverse phase chromatography, and mass spectrometry (Ultraflex TOF / TOF, BRUKER DALTONICS) and amino acid sequence analysis (PROCISE 494cLC protein sequencer, Applied Biosystems) were performed.
逆相クロマトグラフィーによる分離条件
カラム:Inertsil ODS−3(GLサイエンス社製)
測定波長:215nm
流速20μl/分
移動相
A液:0.085%トリフルオロ酢酸水溶液
B液:0.075%トリフルオロ酢酸/80%アセトニトリル液
A液100%から開始し、B液が10分で12.5%、70分で50%、75分で100%になるよう濃度勾配を設けた。
Separation conditions by reverse phase chromatography Column: Inertsil ODS-3 (manufactured by GL Sciences)
Measurement wavelength: 215 nm
実施例1の分子量1112.498のピークなど特定のピークに対しては、A液100%から開始し、B液が20分で100%になるような濃度勾配を設けた。 For specific peaks such as the peak with a molecular weight of 1112.498 in Example 1, a concentration gradient was set so that the liquid B started at 100% and the liquid B reached 100% in 20 minutes.
4−1)ペプチド分解酵素によるクラゲコラーゲンペプチドの作成
実施例1)
凍結乾燥した中性可溶性コラーゲン0.01gを10mLの水に溶解し、1N HClにてpH2に調整した。コラーゲンに対して、0.5質量%のペプシン(試薬、ナカライ製、Pepsin(1:10,000))を加え、37℃にて3時間反応させた。その後、1N NaOHにてpH7に調整してペプシンを失活させた。次にコラーゲンに対して0.5質量%のパパイン(和光純薬製 試薬)を加え、60℃にて3時間反応させ、さらに、コラーゲンに対して0.5質量%のトリプシン(和光純薬製 試薬)を加え、37℃にて3時間反応させた。その後、95℃にて30分間保持して酵素を失活させた。これを凍結乾燥して分子量500〜6000Daのコラーゲンペプチドの混合物を得た。
4-1) Preparation of jellyfish collagen peptide by peptide degrading enzyme Example 1)
0.01 g of lyophilized neutral soluble collagen was dissolved in 10 mL of water and adjusted to
また、質量分析及びアミノ酸配列解析の結果、実施例1のコラーゲンペプチドは、分子量1112.498のコラーゲンペプチドを含み、このコラーゲンペプチドは
アミノ酸配列<1>Gly-Pro-Ala-Gly(配列番号1)
を含むことを確認した。
As a result of mass spectrometry and amino acid sequence analysis, the collagen peptide of Example 1 contains a collagen peptide having a molecular weight of 1112.498. This collagen peptide has an amino acid sequence <1> Gly-Pro-Ala-Gly (SEQ ID NO: 1).
Confirmed to contain.
実施例1の質量分析の結果を図1に、分子量1112.498のアミノ酸配列とタンデム質量分析の予想フラグメント質量の関係を下記の表3に示す。 The results of mass spectrometry of Example 1 are shown in FIG. 1, and the relationship between the amino acid sequence having a molecular weight of 1112.498 and the predicted fragment mass of tandem mass spectrometry is shown in Table 3 below.
実施例2)
実施例1の中性可溶性コラーゲンを、酸性可溶性コラーゲンとした以外は、実施例1と同様の操作を行い、分子量500〜6000Daのコラーゲンペプチドの混合物を得た。
Example 2)
Except that the neutral soluble collagen of Example 1 was changed to acidic soluble collagen, the same operation as in Example 1 was performed to obtain a mixture of collagen peptides having a molecular weight of 500 to 6000 Da.
実施例3)
凍結乾燥した中性可溶性コラーゲン0.01gを10mlの水に溶解し、1N HClにてpH2に調整した。コラーゲンに対して0.5質量%のペプシン(試薬、ナカライ製、Pepsin(1:10,000))を加え、37℃にて3時間反応させた。その後、1N NaOHにてpH8に調整してペプシンを失活させた。これを凍結乾燥して分子量2kDa〜30kDaのコラーゲンペプチドの混合物を得た。
Example 3)
0.01 g of lyophilized neutral soluble collagen was dissolved in 10 ml of water and adjusted to
実施例4)
実施例3の中性可溶性コラーゲンを、酸性可溶性コラーゲンとした以外は、実施例3と同様の操作を行い、分子量2kDa〜30kDaのコラーゲンペプチドの混合物を得た。
Example 4)
A mixture of collagen peptides having a molecular weight of 2 kDa to 30 kDa was obtained in the same manner as in Example 3 except that the neutral soluble collagen of Example 3 was changed to acidic soluble collagen.
実施例5)
実施例3の操作において、ペプシンを失活させた後、コラーゲンに対して0.5質量%のトリプシン(和光純薬製 試薬)を加え、37℃にて3時間反応させた。その後、95℃にて30分処理してトリプシンを失活させた。これを凍結乾燥し、分子量500〜6000Daのコラーゲンペプチドの混合物を得た。
Example 5)
In the operation of Example 3, after inactivating pepsin, 0.5% by mass of trypsin (a reagent manufactured by Wako Pure Chemical Industries, Ltd.) was added to collagen and reacted at 37 ° C. for 3 hours. Subsequently, trypsin was inactivated by treatment at 95 ° C. for 30 minutes. This was freeze-dried to obtain a mixture of collagen peptides having a molecular weight of 500 to 6000 Da.
実施例6)
実施例5の中性可溶性コラーゲンを、酸性可溶性コラーゲンとした以外は、実施例5と同様の操作を行い、分子量500〜6000Daのコラーゲンペプチドの混合物を得た。
Example 6)
A mixture of collagen peptides having a molecular weight of 500 to 6000 Da was obtained by performing the same operation as in Example 5 except that the neutral soluble collagen of Example 5 was changed to acidic soluble collagen.
実施例7)
実施例3の操作において、37℃にて3時間反応させた後、1N NaOHでpH7に調整してペプシンを失活させた後、コラーゲンに対して0.5質量%のパパイン(和光純薬製 試薬)を加え、60℃にて3時間反応させた。その後、95℃、30分の条件でパパインを失活させ、凍結乾燥にて分子量1kDa〜20kDaのコラーゲンペプチドの混合物を得た。
Example 7)
In the operation of Example 3, after reacting at 37 ° C. for 3 hours, pH was adjusted to 7 with 1N NaOH to inactivate pepsin, and then 0.5% by mass of papain (manufactured by Wako Pure Chemical Industries, Ltd.) with respect to collagen. Reagent) and reacted at 60 ° C. for 3 hours. Thereafter, papain was inactivated at 95 ° C. for 30 minutes, and a mixture of collagen peptides having a molecular weight of 1 kDa to 20 kDa was obtained by lyophilization.
実施例8)
実施例7の中性可溶性コラーゲンを、酸性可溶性コラーゲンとした以外は、実施例7と同様の操作を行い、分子量1kDa〜20kDaのコラーゲンペプチドの混合物を得た。
Example 8)
A mixture of collagen peptides having a molecular weight of 1 kDa to 20 kDa was obtained in the same manner as in Example 7 except that the neutral soluble collagen of Example 7 was changed to acidic soluble collagen.
固体酸触媒によるクラゲコラーゲンペプチドの作成
実施例9)
陽イオン交換樹脂(TOYOPEARL SP−550C)0.5gと、1質量%の中性可溶性コラーゲン水溶液0.5mLとを混合して、陽イオン交換樹脂に中性可溶性コラーゲンを吸着させた後、90℃にて30分加熱し、中性可溶性コラーゲンを加水分解した。冷却後、5%トリエチルアミン/10%アセトニトリル液にて樹脂から分解物を抽出した。これを凍結乾燥し、分子量2kDa〜20kDaのコラーゲンペプチドの混合物を得た。
Preparation of jellyfish collagen peptide by solid acid catalyst Example 9)
After mixing 0.5 g of cation exchange resin (TOYOPEARL SP-550C) and 0.5 mL of 1% by mass neutral soluble collagen aqueous solution to adsorb neutral soluble collagen to the cation exchange resin, 90 ° C. For 30 minutes to hydrolyze neutral soluble collagen. After cooling, the decomposition product was extracted from the resin with 5% triethylamine / 10% acetonitrile solution. This was freeze-dried to obtain a mixture of collagen peptides having a molecular weight of 2 kDa to 20 kDa.
また、実施例9のコラーゲンペプチドの質量分析及びアミノ酸配列解析の結果、分子量1950.915のコラーゲンペプチドを含み、分子量1950.915のコラーゲンペプチドは、
アミノ酸配列<2>Pro-Gly-Val-Lys-Gly-Glu-Val-Gly-Glu-Ala-Gly-Lys-Arg-Gly(配列番号2)
を含むことを確認した。
Moreover, as a result of mass spectrometry and amino acid sequence analysis of the collagen peptide of Example 9, the collagen peptide having a molecular weight of 1950.915 was included, and the collagen peptide having a molecular weight of 1950.915 was
Amino acid sequence <2> Pro-Gly-Val-Lys-Gly-Glu-Val-Gly-Glu-Ala-Gly-Lys-Arg-Gly (SEQ ID NO: 2)
Confirmed to contain.
実施例9の質量分析の結果を図2に、分子量1950.915のアミノ酸配列とタンデム質量分析の予想フラグメント質量の関係を下記の表4に示す。 The results of mass spectrometry of Example 9 are shown in FIG. 2, and the relationship between the amino acid sequence having a molecular weight of 1950.915 and the predicted fragment mass of tandem mass spectrometry is shown in Table 4 below.
実施例10)
実施例9の加熱時間を15分とした以外は、実施例9と同様の操作を行い、分子量6kDa〜100kDaのコラーゲンペプチドの混合物を得た。
Example 10)
A mixture of collagen peptides having a molecular weight of 6 kDa to 100 kDa was obtained in the same manner as in Example 9, except that the heating time in Example 9 was changed to 15 minutes.
実施例11)
実施例9の加熱時間を60分とした以外は、実施例9と同様の操作を行い、分子量1kDa〜10kDaのコラーゲンペプチドの混合物を得た。
Example 11)
A mixture of collagen peptides having a molecular weight of 1 kDa to 10 kDa was obtained by performing the same operation as in Example 9, except that the heating time of Example 9 was changed to 60 minutes.
実施例12)
実施例9の加熱温度を110℃、加熱時間を5分とした以外は、実施例9と同様の操作を行い、分子量1kDa〜10kDaのコラーゲンペプチドの混合物を得た。
Example 12)
A mixture of collagen peptides having a molecular weight of 1 kDa to 10 kDa was obtained in the same manner as in Example 9, except that the heating temperature of Example 9 was 110 ° C. and the heating time was 5 minutes.
実施例13)
実施例12の加熱時間を30分とした以外は、実施例12と同様の操作を行い、分子量1kDa〜5kDaのコラーゲンペプチドの混合物を得た。
Example 13)
Except that the heating time of Example 12 was 30 minutes, the same operation as in Example 12 was performed to obtain a mixture of collagen peptides having a molecular weight of 1 kDa to 5 kDa.
実施例14)
実施例12の加熱時間を60分とした以外は、実施例12と同様の操作を行い、分子量200〜2000Daのコラーゲンペプチドの混合物を得た。
Example 14)
Except that the heating time of Example 12 was 60 minutes, the same operation as in Example 12 was performed to obtain a mixture of collagen peptides having a molecular weight of 200 to 2000 Da.
実施例15)
実施例12の加熱時間を2時間とした以外は、実施例12と同様の操作を行い、分子量200〜1000Daのコラーゲンペプチドの混合物を得た。
Example 15)
Except that the heating time of Example 12 was 2 hours, the same operation as in Example 12 was performed to obtain a mixture of collagen peptides having a molecular weight of 200 to 1000 Da.
実施例16)
実施例12の加熱時間を4時間とした以外は、実施例12と同様の操作を行い、分子量200〜1000Daのコラーゲンペプチドの混合物を得た。
Example 16)
Except that the heating time of Example 12 was changed to 4 hours, the same operation as in Example 12 was performed to obtain a mixture of collagen peptides having a molecular weight of 200 to 1000 Da.
実施例12〜14の分子量分布を図3に示した。 The molecular weight distributions of Examples 12 to 14 are shown in FIG.
5.臭化シアン分解コラーゲンペプチドの解析
凍結乾燥した中性可溶性コラーゲンに、中性可溶性コラーゲンに対して10質量%の臭化シアンを添加し、37℃にて20時間反応して中性可溶性コラーゲンの加水分解物を得た。メチオニンのC末端側で切断する臭化シアンによる加水分解は、特異性が高くアミノ酸配列の解析に一般的に用いられる方法である。中性可溶性コラーゲンの加水分解物を濃縮遠心して臭化シアンを揮発させた後、水に再溶解し、ゲル濃度5〜20質量%のアクリルアミドゲル(バイオクラフト製)を用いて、SDS−ポリアクリルアミドゲル電気泳動法にて分離した。得られたゲル情報を電圧60VにてPVDF膜に4時間ブロット転写し、転写されたバンドをプロテインシークエンサー(PROCISE 494HT、Applied Biosystems)で解析して、次のアミノ酸配列情報を得た。
5. Analysis of cyanogen bromide-degrading collagen peptide 10% by mass of cyanogen bromide was added to lyophilized neutral soluble collagen and reacted at 37 ° C for 20 hours to hydrolyze neutral soluble collagen. A decomposition product was obtained. Hydrolysis with cyanogen bromide that cleaves at the C-terminal side of methionine is a method that has high specificity and is generally used for analysis of amino acid sequences. The neutral soluble collagen hydrolyzate was concentrated and centrifuged to volatilize cyanogen bromide, then redissolved in water, and SDS-polyacrylamide using an acrylamide gel (manufactured by Biocraft) with a gel concentration of 5 to 20% by mass. Separation was performed by gel electrophoresis. The obtained gel information was blot transferred onto a PVDF membrane at a voltage of 60 V for 4 hours, and the transferred band was analyzed with a protein sequencer (PROCISE 494HT, Applied Biosystems) to obtain the following amino acid sequence information.
アミノ酸配列<3>Val-Gly-Pro-Val-Thr-Glu-Glu-Val-Ser-Pro-Ala-Lys(配列番号3)
アミノ酸配列<4>Ser-Ala-Gly-Gln-Asn-Pro-Ala-Asp-Asp-Val(配列番号4)
アミノ酸配列<5>Gly-Thr-Pro(OH)-Gly-Ala-Gly-Gly-Ser-Arg(配列番号5)
アミノ酸配列<6>Gln-Gly-Pro-Gln-Gly-Glu-Leu(配列番号6)
Pro(OH)はヒドロキシプロリンを示す。
Amino acid sequence <3> Val-Gly-Pro-Val-Thr-Glu-Glu-Val-Ser-Pro-Ala-Lys (SEQ ID NO: 3)
Amino acid sequence <4> Ser-Ala-Gly-Gln-Asn-Pro-Ala-Asp-Asp-Val (SEQ ID NO: 4)
Amino acid sequence <5> Gly-Thr-Pro (OH) -Gly-Ala-Gly-Gly-Ser-Arg (SEQ ID NO: 5)
Amino acid sequence <6> Gln-Gly-Pro-Gln-Gly-Glu-Leu (SEQ ID NO: 6)
Pro (OH) represents hydroxyproline.
前記アミノ酸配列<1>(ペプチド分解酵素による分解物)、アミノ酸配列<2>(固体酸触媒による分解物)、及び上記のアミノ酸配列<3>〜<6>は、いずれもクラゲコラーゲンに含まれるアミノ酸の配列であり、加水分解前のクラゲコラーゲンはアミノ酸配列<
1>〜<6>のすべてを有するものである。したがって、このクラゲコラーゲンを加水分解して得られるクラゲコラーゲンペプチドの混合物は、分解の手段に関わらず、アミノ酸配列<1>〜<6>を含むコラーゲンペプチドを含有するものとなる。
The amino acid sequence <1> (degraded product by peptide degrading enzyme), amino acid sequence <2> (degraded product by solid acid catalyst), and the above amino acid sequences <3> to <6> are all contained in jellyfish collagen. It is an amino acid sequence, and jellyfish collagen before hydrolysis is amino acid sequence <
It has all of 1> to <6>. Therefore, the jellyfish collagen peptide mixture obtained by hydrolyzing the jellyfish collagen contains a collagen peptide containing amino acid sequences <1> to <6> regardless of the means of degradation.
これら6種のアミノ酸配列のうち、アミノ酸配列<3>〜<6>のアミノ酸配列からなるペプチドの合成物(北海道システムサイエンス株式会社に製造を委託)を準備し、これを実施例17〜20とした。 Among these six kinds of amino acid sequences, a synthetic product of peptides consisting of amino acid sequences <3> to <6> (consignment of production to Hokkaido System Science Co., Ltd.) was prepared. did.
実施例17)Val-Gly-Pro-Val-Thr-Glu-Glu-Val-Ser-Pro-Ala-Lys(配列番号3)
実施例18)Ser-Ala-Gly-Gln-Asn-Pro-Ala-Asp-Asp-Val(配列番号4)
実施例19)Gly-Thr-Pro(OH)-Gly-Ala-Gly-Gly-Ser-Arg(配列番号5)
実施例20)Gln-Gly-Pro-Gln-Gly-Glu-Leu(配列番号6)
Example 17) Val-Gly-Pro-Val-Thr-Glu-Glu-Val-Ser-Pro-Ala-Lys (SEQ ID NO: 3)
Example 18) Ser-Ala-Gly-Gln-Asn-Pro-Ala-Asp-Asp-Val (SEQ ID NO: 4)
Example 19) Gly-Thr-Pro (OH) -Gly-Ala-Gly-Gly-Ser-Arg (SEQ ID NO: 5)
Example 20) Gln-Gly-Pro-Gln-Gly-Glu-Leu (SEQ ID NO: 6)
6.クラゲコラーゲンペプチドの効果の評価
評価試験1(角化細胞を用いた賦活試験)
細胞賦活化作用は、活化培養細胞と細胞増殖試薬WST−1(ロシュ製)とを用いた細胞増殖効果で評価した。
6). Evaluation test 1 of the effect of jellyfish collagen peptide (activation test using keratinocytes)
The cell activation effect was evaluated by the cell proliferation effect using activated cultured cells and the cell proliferation reagent WST-1 (Roche).
ヒューマンサイエンス振興財団より分譲されたヒト皮膚由来不死化角化細胞PHK16−0bを48wellマルチプレートに2×104個播種し、300μLのKGM培地を加えて2日間培養した。その後、クラゲコラーゲン濃度10μg/mLのKGM培地300μLと交換し、37℃のインキュベーター内で7日間培養した。再度新しいKGM培地270μLと交換し、細胞増殖試薬WST−1を30μL加えて37℃のインキュベーター内で3時間反応した後、培地の440nmにおける吸光度を測定した。コラーゲンペプチドを添加せずに、同条件にて培養したコントロールの細胞生存率を100%とし、コラーゲンペプチドの細胞増殖率を評価(n=3)した。結果を次に示す。 2 × 10 4 human skin-derived immortalized keratinocytes PHK16-0b distributed by the Human Science Promotion Foundation were seeded on a 48-well multiplate, and 300 μL of KGM medium was added and cultured for 2 days. Thereafter, the medium was replaced with 300 μL of KGM medium having a jellyfish collagen concentration of 10 μg / mL, and the cells were cultured in an incubator at 37 ° C. for 7 days. The medium was replaced with 270 μL of new KGM medium again, 30 μL of cell growth reagent WST-1 was added, and the mixture was reacted in a 37 ° C. incubator for 3 hours, and then the absorbance at 440 nm of the medium was measured. The cell growth rate of the control cultured under the same conditions without adding the collagen peptide was taken as 100%, and the cell growth rate of the collagen peptide was evaluated (n = 3). The results are shown below.
いずれの加水分解条件で得られたクラゲコラーゲンペプチドにも細胞増殖効果が確認され、ペプチド分解酵素では、ペプシンによる加水分解したのち、さらに、パパイン及びトリプシンで加水分解して得られたコラーゲンペプチドに特に優れた効果が認められた。 Jellyfish collagen peptide obtained under any hydrolysis conditions was confirmed to have a cell growth effect. Peptide degrading enzymes are particularly useful for collagen peptides obtained by hydrolysis with pepsin and then with papain and trypsin. Excellent effect was observed.
固体酸触媒で得られたクラゲコラーゲンペプチドの細胞増殖効果も良好であり、110℃処理では処理時間が30分以内のクラゲコラーゲンペプチドで良好な結果が得られた、クラゲコラーゲンのアミノ酸配列情報を元に製造したペプチドの細胞増殖効果も良好であり、特に実施例17で卓越した効果が確認できた。一方、クラゲコラーゲン自体には、中性可溶性コラーゲン(比較例1)、酸性可溶性コラーゲン(比較例2)共に細胞増殖効果を確認できなかった。 Based on the amino acid sequence information of jellyfish collagen, the jellyfish collagen peptide obtained with the solid acid catalyst has a good cell growth effect, and with 110 ° C treatment, good results were obtained with the jellyfish collagen peptide with a treatment time of 30 minutes or less. The cell proliferation effect of the peptide produced in Example 1 was also good, and in particular, the excellent effect was confirmed in Example 17. On the other hand, for the jellyfish collagen itself, the cell growth effect could not be confirmed for both neutral soluble collagen (Comparative Example 1) and acidic soluble collagen (Comparative Example 2).
評価試験2(角化細胞を用いたインボルクリン発現量試験)
成人ヒト皮膚由来正常角化細胞(コージンバイオ製)を、48wellマルチプレートに1×105個ずつ播種し、これにKGM培地を300μL加えて37℃にて24時間培養した、クラゲコラーゲンペプチド濃度10μg/mLのKGM培地300μLに交換し、37℃にて48時間培養した。細胞を回収し、ウエスタンブロット法にてインボルクリン産生量を測定した。なお、一次抗体として、抗ヒトインボルクリン(コスモバイオ、sc−28557)を、二次抗体として、抗ウサギIgG−HRP(コスモバイオ、sc−2004)を用いた。結果をImageJで解析し、無添加群(コントロール)に対する
インボルクリン発現率を評価した。結果を次に示す。
Evaluation test 2 (Involucrin expression level test using keratinocytes)
Adult human skin-derived normal keratinocytes (manufactured by Kojin Bio) were seeded on a 48-well multiplate at 1 × 10 5 cells, and 300 μL of KGM medium was added thereto and cultured at 37 ° C. for 24 hours. Jellyfish collagen peptide concentration 10 μg The medium was replaced with 300 μL / mL KGM medium and cultured at 37 ° C. for 48 hours. Cells were collected, and involucrin production was measured by Western blotting. In addition, anti-human involucrin (Cosmo Bio, sc-28557) was used as the primary antibody, and anti-rabbit IgG-HRP (Cosmo Bio, sc-2004) was used as the secondary antibody. The results were analyzed by ImageJ, and the involucrin expression rate relative to the additive-free group (control) was evaluated. The results are shown below.
クラゲコラーゲンをペプチド分解酵素および固体酸触媒で加水分解して得られたクラゲコラーゲンペプチドの混合物に良好なインボルクリン発現効果を確認した。アミノ酸配列情報に基づき合成して得られたペプチドにも、インボルクリン産生効果が認められた。
評価試験3(角化細胞を用いたトランスグルタミナーゼ1発現量試験)
ヒト皮膚由来不死化角化細胞PHK16−0bを48wellマルチプレートに20×104個播種し、これにKGM培地を300μL加えて37℃にて24時間培養した。クラゲコラーゲンペプチド濃度10μg/mLのKGM培地300μLに交換して、37℃にて48時間培養した後に細胞を回収し、ウエスタンブロット法にてトランスグルタミナーゼ1産生量を測定した。なお、一次抗体として抗トランスグルタミナーゼ1(コスモバイオ、PAB15545)を、二次抗体として抗ウサギIgG−HRP(コスモバイオ、sc−2004)を用いた。結果をImageJで解析し、無添加群(コントロール)に対するトランスグルタミナーゼ1発現率を評価した。結果を次に示す。
A good involucrin expression effect was confirmed in a mixture of jellyfish collagen peptides obtained by hydrolyzing jellyfish collagen with a peptide degrading enzyme and a solid acid catalyst. A peptide obtained by synthesis based on amino acid sequence information was also found to have an involucrin production effect.
Evaluation test 3 (Transglutaminase 1 expression level test using keratinocytes)
20 × 10 4 human skin-derived immortalized keratinocytes PHK16-0b were seeded on a 48-well multiplate, and 300 μL of KGM medium was added thereto and cultured at 37 ° C. for 24 hours. After replacing with 300 μL of KGM medium having a jellyfish collagen peptide concentration of 10 μg / mL and culturing at 37 ° C. for 48 hours, the cells were collected, and the amount of transglutaminase 1 produced was measured by Western blotting. Note that anti-transglutaminase 1 (Cosmo Bio, PAB15545) was used as the primary antibody, and anti-rabbit IgG-HRP (Cosmo Bio, sc-2004) was used as the secondary antibody. The results were analyzed by ImageJ, and the transglutaminase 1 expression rate relative to the non-added group (control) was evaluated. The results are shown below.
クラゲコラーゲンをペプチド分解酵素で加水分解して得られたクラゲコラーゲンペプチドの混合物に良好なトランスグルタミナーゼ1発現効果を確認することができた。固体酸触媒で加水分解して得られたクラゲコラーゲンペプチド混合物およびアミノ酸配列情報に基づき合成して得られたペプチドにもトランスグルタミナーゼ1産生効果が確認できた。 A favorable transglutaminase 1 expression effect could be confirmed in a mixture of jellyfish collagen peptides obtained by hydrolyzing jellyfish collagen with a peptide degrading enzyme. The effect of producing transglutaminase 1 was also confirmed in a jellyfish collagen peptide mixture obtained by hydrolysis with a solid acid catalyst and a peptide obtained by synthesis based on amino acid sequence information.
評価試験4(角化細胞を用いたCOX−2阻害効果試験)
抗炎症効果は、紫外線照射を受けた角化細胞のCOX−2が産生するPGE2の量で評価した。PGE2産生量が少ないほど、クラゲコラーゲンペプチドは抗炎症性を有するものとなる。
Evaluation test 4 (COX-2 inhibitory effect test using keratinocytes)
The anti-inflammatory effect was evaluated by the amount of PGE 2 produced by COX-2 of keratinocytes that had received ultraviolet irradiation. The smaller the amount of PGE 2 produced, the more the jellyfish collagen peptide has anti-inflammatory properties.
ヒト皮膚由来不死化角化細胞PHK16−0bを48wellマルチプレートに20×104個播種し、KGM培地を300μL加えて、一晩培養した。アスピリン濃度500μMのKGM培地300μLに交換し4時間培養して、既に発現しているCOX−2を失活させた。PBS(−)での洗浄を3回繰り返し、クラゲコラーゲンペプチド濃度を10μg/mLとしたDMEM培地に交換し、50mJのUVBを照射した後、48時間培養した。その後、培地上清中のPGE2量をプロスタグランジンE2 EIAキット(Cayman Chemical製)にて測定(n=3)した。 20 × 10 4 human skin-derived immortalized keratinocytes PHK16-0b were seeded on a 48-well multiplate, and 300 μL of KGM medium was added and cultured overnight. The medium was replaced with 300 μL of KGM medium having an aspirin concentration of 500 μM and cultured for 4 hours to inactivate COX-2 that had already been expressed. Washing with PBS (−) was repeated three times, and the medium was replaced with a DMEM medium with a jellyfish collagen peptide concentration of 10 μg / mL. After irradiation with 50 mJ of UVB, the cells were cultured for 48 hours. Thereafter, the amount of PGE 2 in the culture supernatant was measured with a prostaglandin E 2 EIA kit (manufactured by Cayman Chemical) (n = 3).
クラゲコラーゲンペプチド混合物に、良好な抗炎症効果が確認でき、特に、クラゲコラーゲンをペプシンで分解した後、さらにトリプシンで分解して得られたクラゲコラーゲンペプチドの混合物に優れた抗炎症効果を確認することができた。
7.化粧料への配合例
A成分、B成分をそれぞれ80℃に加温して溶解し、撹拌しながらB成分をA成分に徐々に加えて乳化した。その後撹拌しながら冷却し、40℃で0.2質量%水溶液に調整したC成分を加え、全身用ローションを調整した。
(A)成分
グレープシード油 0.1(g)
ポリオキシエチレン(60モル)硬化ヒマシ油 0.7
モノイソステアリン酸ジグリセリル 0.3
(B)成分
クエン酸 0.08
クエン酸Na 0.3
1,3−ブタンジオール 5
グリセリン 3
エタノール 5
キサンタンガム 0.1
メチルパラベン 0.2
精製水 残量
(C)成分
クラゲコラーゲンペプチド(0.2質量%) 0.5
計 100
A good anti-inflammatory effect can be confirmed in the jellyfish collagen peptide mixture, and in particular, an excellent anti-inflammatory effect should be confirmed in the jellyfish collagen peptide mixture obtained by degrading jellyfish collagen with pepsin and then further digesting with trypsin. I was able to.
7). Formulation Example for Cosmetics Each of the A component and the B component was heated to 80 ° C. to dissolve, and the B component was gradually added to the A component and emulsified with stirring. Thereafter, the mixture was cooled with stirring, and a C component adjusted to a 0.2 mass% aqueous solution at 40 ° C. was added to prepare a lotion for whole body.
(A) component
Grape seed oil 0.1 (g)
Polyoxyethylene (60 mol) hydrogenated castor oil 0.7
Diglyceryl monoisostearate0.3
(B) component
Citric acid 0.08
Na citrate 0.3
1,3-butanediol 5
Ethanol 5
Xanthan gum 0.1
Methylparaben 0.2
Purified water Remaining (C) component
Jellyfish collagen peptide (0.2% by mass) 0.5
Total 100
評価
前記組成の全身用ローションを、1日に2回(朝、夜)、顔面、及び前腕に適宜使用し、顔面および前腕の片側には実施例1〜20のクラゲコラーゲンペプチドを配合した化粧料または酸性可溶性コラーゲン(比較例2)を配合した化粧料を、もう一方には、中性可溶性コラーゲン(比較例1)を配合した化粧料を使用した。これを1ヶ月間継続し、次の評価基準で判定した。結果を表9に示す。
なお、この使用期間中に皮膚の異常を訴えたものはいなかった。
Evaluation A lotion for whole body having the above composition is used twice a day (morning and night) as needed on the face and forearm, and cosmetics containing the jellyfish collagen peptide of Examples 1 to 20 on one side of the face and forearm Or the cosmetics which mix | blended acidic soluble collagen (comparative example 2) and the cosmetics which mix | blended neutral soluble collagen (comparative example 1) were used for the other. This was continued for one month and judged according to the following evaluation criteria. The results are shown in Table 9.
No one complained of skin abnormalities during this period of use.
スコア値
+3:比較例1を配合した化粧料よりも潤いを強く感じた
+2:比較例1を配合した化粧料よりもかなり潤いを感じられた
+1:比較例1を配合した化粧料よりもやや潤いを感じられた
0:差がない
−1:比較例1を配合した化粧料の方がやや潤いを感じられた
−2:比較例1を配合した化粧料の方がかなり潤いを感じられた
−3:比較例1を配合した化粧料の方が潤い強く感じた
Score value +3: felt moisturizing stronger than the cosmetics formulated with Comparative Example 1 +2: felt moisturized significantly more than the cosmetics formulated with Comparative Example 1 +1: slightly higher than the cosmetics formulated with Comparative Example 1 Moisture was felt 0: No difference -1: Cosmetics formulated with Comparative Example 1 felt slightly moisturized-2: Cosmetics formulated with Comparative Example 1 felt significantly moisturized -3: The cosmetic containing Comparative Example 1 felt moist and strong
いずれのクラゲコラーゲンペプチドの混合物においても、中性可溶性コラーゲンを配合した化粧料を上回る肌の潤い効果を得ることができた。 In any mixture of jellyfish collagen peptides, it was possible to obtain a skin moisturizing effect that exceeded that of cosmetics containing neutral soluble collagen.
ペプチド分解酵素による加水分解物としては、中性または酸性可溶性コラーゲンをペプシンで加水分解の後、さらにパパインおよびトリプシンで加水分解して得られたクラゲコラーゲンペプチド混合物で、特に良好な潤い効果が得られた。 Peptide degrading enzyme hydrolyzate is a jellyfish collagen peptide mixture obtained by hydrolyzing neutral or acidic soluble collagen with pepsin and then hydrolyzing with papain and trypsin. It was.
固体酸触媒による加水分解物では、処理温度90℃、処理時間30分間の処理で得られたクラゲコラーゲンペプチド混合物に良好な潤い効果が認められた。 In the hydrolyzate by a solid acid catalyst, a good moistening effect was observed in the jellyfish collagen peptide mixture obtained by the treatment at a treatment temperature of 90 ° C. and a treatment time of 30 minutes.
クラゲコラーゲンのアミノ酸配列情報に基づき合成したペプチドを配合した化粧料においても、肌の潤い効果は良好であった。 Even in cosmetics containing a peptide synthesized based on amino acid sequence information of jellyfish collagen, the skin moisturizing effect was good.
クラゲコラーゲンに由来するコラーゲンペプチドを用いることにより、角化細胞賦活効果、インボルクリン産生促進効果、トランスグルタミナーゼ産生促進効果、抗炎症効果を得ることができるため、これを経皮投与することにより、角質のバリア機能を修復改善し、表皮角化細胞の機能が正常化することが可能となる。 By using a collagen peptide derived from jellyfish collagen, keratinocyte activation effect, involucrin production promotion effect, transglutaminase production promotion effect and anti-inflammatory effect can be obtained. The barrier function is repaired and improved, and the function of the epidermal keratinocytes can be normalized.
Claims (13)
<1>Gly-Pro-Ala-Gly(配列番号1)
<2>Pro-Gly-Val-Lys-Gly-Glu-Val-Gly-Glu-Ala-Gly-Lys-Arg-Gly(配列番号2)
<3>Val-Gly-Pro-Val-Thr-Glu-Glu-Val-Ser-Pro-Ala-Lys(配列番号3)
<4>Ser-Ala-Gly-Gln-Asn-Pro-Ala-Asp-Asp-Val(配列番号4)
<5>Gly-Thr-Pro(OH)-Gly-Ala-Gly-Gly-Ser-Arg(配列番号5)
<6>Gln-Gly-Pro-Gln-Gly-Glu-Leu(配列番号6)
Pro(OH)はヒドロキシプロリンを示す。 A jellyfish collagen peptide mixture containing a jellyfish collagen peptide comprising any of the following amino acid sequences.
<1> Gly-Pro-Ala-Gly (SEQ ID NO: 1)
<2> Pro-Gly-Val-Lys-Gly-Glu-Val-Gly-Glu-Ala-Gly-Lys-Arg-Gly (SEQ ID NO: 2)
<3> Val-Gly-Pro-Val-Thr-Glu-Glu-Val-Ser-Pro-Ala-Lys (SEQ ID NO: 3)
<4> Ser-Ala-Gly-Gln-Asn-Pro-Ala-Asp-Asp-Val (SEQ ID NO: 4)
<5> Gly-Thr-Pro (OH) -Gly-Ala-Gly-Gly-Ser-Arg (SEQ ID NO: 5)
<6> Gln-Gly-Pro-Gln-Gly-Glu-Leu (SEQ ID NO: 6)
Pro (OH) represents hydroxyproline.
<1>Gly-Pro-Ala-Gly(配列番号1)
<2>Pro-Gly-Val-Lys-Gly-Glu-Val-Gly-Glu-Ala-Gly-Lys-Arg-Gly(配列番号2)
<3>Val-Gly-Pro-Val-Thr-Glu-Glu-Val-Ser-Pro-Ala-Lys(配列番号3)
<4>Ser-Ala-Gly-Gln-Asn-Pro-Ala-Asp-Asp-Val(配列番号4)
<5>Gly-Thr-Pro(OH)-Gly-Ala-Gly-Gly-Ser-Arg(配列番号5)
<6>Gln-Gly-Pro-Gln-Gly-Glu-Leu(配列番号6)
Pro(OH)はヒドロキシプロリンを示す。 A peptide comprising any of the following amino acid sequences.
<1> Gly-Pro-Ala-Gly (SEQ ID NO: 1)
<2> Pro-Gly-Val-Lys-Gly-Glu-Val-Gly-Glu-Ala-Gly-Lys-Arg-Gly (SEQ ID NO: 2)
<3> Val-Gly-Pro-Val-Thr-Glu-Glu-Val-Ser-Pro-Ala-Lys (SEQ ID NO: 3)
<4> Ser-Ala-Gly-Gln-Asn-Pro-Ala-Asp-Asp-Val (SEQ ID NO: 4)
<5> Gly-Thr-Pro (OH) -Gly-Ala-Gly-Gly-Ser-Arg (SEQ ID NO: 5)
<6> Gln-Gly-Pro-Gln-Gly-Glu-Leu (SEQ ID NO: 6)
Pro (OH) represents hydroxyproline.
請求項8に記載のペプチドを含有するトランスグルタミナーゼ産生促進剤。 The transglutaminase production promoter containing the jellyfish collagen peptide mixture of any one of Claims 1-7, and / or the peptide of Claim 8.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011240469A JP2013095708A (en) | 2011-11-01 | 2011-11-01 | Medusa collagen peptide mixture |
KR1020120120347A KR20130048164A (en) | 2011-11-01 | 2012-10-29 | Jellyfish collagen peptide mixture |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011240469A JP2013095708A (en) | 2011-11-01 | 2011-11-01 | Medusa collagen peptide mixture |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2013095708A true JP2013095708A (en) | 2013-05-20 |
Family
ID=48618031
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011240469A Pending JP2013095708A (en) | 2011-11-01 | 2011-11-01 | Medusa collagen peptide mixture |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP2013095708A (en) |
KR (1) | KR20130048164A (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015098634A1 (en) | 2013-12-25 | 2015-07-02 | 株式会社海月研究所 | Continuous production method for decomposition product from water-insoluble macromolecular compound |
CN106546680A (en) * | 2016-10-27 | 2017-03-29 | 华南理工大学 | The rapid assay methods of polypeptide molecular weight in a kind of hydrolytic collagen oral liquid |
WO2020205848A1 (en) * | 2019-04-01 | 2020-10-08 | Geltor, Inc. | Topical formulations of recombinant collagens |
US11028148B2 (en) | 2017-09-28 | 2021-06-08 | Geltor, Inc. | Recombinant collagen and elastin molecules and uses thereof |
JP2021097626A (en) * | 2019-12-20 | 2021-07-01 | 国立大学法人東京農工大学 | Low-molecular-weight collagen peptide composition and method for producing the same |
US11168126B2 (en) | 2019-04-12 | 2021-11-09 | Geltor, Inc. | Recombinant elastin and production thereof |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102080138B1 (en) * | 2012-08-23 | 2020-02-21 | 가부시키가이샤 구라게 겡큐쇼 | Method for fractionally extracting mucin and collagen |
-
2011
- 2011-11-01 JP JP2011240469A patent/JP2013095708A/en active Pending
-
2012
- 2012-10-29 KR KR1020120120347A patent/KR20130048164A/en not_active Application Discontinuation
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015098634A1 (en) | 2013-12-25 | 2015-07-02 | 株式会社海月研究所 | Continuous production method for decomposition product from water-insoluble macromolecular compound |
KR20160102256A (en) | 2013-12-25 | 2016-08-29 | 가부시키가이샤 구라게 겡큐쇼 | Continuous production method for decomposition product from water-insoluble macromolecular compound |
CN106061991A (en) * | 2013-12-25 | 2016-10-26 | 株式会社海月研究所 | Continuous production method for decomposition product from water-insoluble macromolecular compound |
JPWO2015098634A1 (en) * | 2013-12-25 | 2017-03-23 | 株式会社海月研究所 | Continuous production method of degradation product of water-insoluble polymer compound |
US10239915B2 (en) | 2013-12-25 | 2019-03-26 | Jellyfish Research Laboratories, Inc. | Method for continuous production of degradation product of water-insoluble polymeric compound |
CN106546680A (en) * | 2016-10-27 | 2017-03-29 | 华南理工大学 | The rapid assay methods of polypeptide molecular weight in a kind of hydrolytic collagen oral liquid |
US11028148B2 (en) | 2017-09-28 | 2021-06-08 | Geltor, Inc. | Recombinant collagen and elastin molecules and uses thereof |
US11041015B2 (en) | 2017-09-28 | 2021-06-22 | Geltor, Inc. | Recombinant collagen and elastin molecules and uses thereof |
US11180541B2 (en) | 2017-09-28 | 2021-11-23 | Geltor, Inc. | Recombinant collagen and elastin molecules and uses thereof |
US11214609B2 (en) | 2017-09-28 | 2022-01-04 | Geltor, Inc. | Recombinant collagen and elastin molecules and uses thereof |
CN112469432A (en) * | 2019-04-01 | 2021-03-09 | 格尔托公司 | Topical formulations of recombinant collagen |
WO2020205848A1 (en) * | 2019-04-01 | 2020-10-08 | Geltor, Inc. | Topical formulations of recombinant collagens |
KR20210076144A (en) * | 2019-04-01 | 2021-06-23 | 젤터, 인코포레이티드 | Topical formulations of recombinant collagen |
GB2596998A (en) * | 2019-04-01 | 2022-01-12 | Geltor Inc | Topical formulations of recombinant collagens |
KR102529881B1 (en) | 2019-04-01 | 2023-05-04 | 젤터, 인코포레이티드 | Topical formulation of recombinant collagen |
GB2596998B (en) * | 2019-04-01 | 2023-10-04 | Geltor Inc | Topical formulations of recombinant collagens |
US11168126B2 (en) | 2019-04-12 | 2021-11-09 | Geltor, Inc. | Recombinant elastin and production thereof |
JP2021097626A (en) * | 2019-12-20 | 2021-07-01 | 国立大学法人東京農工大学 | Low-molecular-weight collagen peptide composition and method for producing the same |
Also Published As
Publication number | Publication date |
---|---|
KR20130048164A (en) | 2013-05-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7227903B2 (en) | Compounds useful for the treatment and/or care of skin, hair, nails and/or mucous membranes | |
JP2013095708A (en) | Medusa collagen peptide mixture | |
ES2399581T3 (en) | Cosmetic or pharmaceutical compositions comprising metalloproteinase inhibitors | |
ES2547762T3 (en) | Peptides for use in the cosmetic or pharmaceutical treatment of the skin, mucous membranes and / or scalp | |
KR100613554B1 (en) | Cosmetics | |
JP7200211B2 (en) | Compounds useful for the treatment and/or care of skin, hair, nails and/or mucous membranes | |
TWI474838B (en) | Peptides useful in the treatment and/or care of skin, mucous membranes, scalp and/or hair and their use in cosmetic or pharmaceutical compositions | |
JPH08231370A (en) | Skin cosmetic | |
US11759544B2 (en) | Therapeutic compositions for enhanced healing of wounds and scars | |
JP2016502550A (en) | Compounds useful in the treatment and / or care of skin, hair and / or mucous membranes and their cosmetic or pharmaceutical compositions | |
US8877713B2 (en) | Anti-aging peptides and cosmetic and/or pharmaceutical composition containing same | |
JP2011514891A5 (en) | ||
JP7526159B2 (en) | Compounds useful in the treatment and/or care of the skin, hair, nails and/or mucous membranes | |
JP3504205B2 (en) | External preparation for skin | |
KR20210126037A (en) | Compounds useful for the treatment and/or care of skin, hair, nails and/or mucous membranes | |
CN114315960A (en) | Modified peptide, and cosmetic composition or medicinal composition and application thereof | |
JP4950571B2 (en) | Composition having ability to promote collagen production | |
JP3249844B2 (en) | Skin cosmetics | |
EP4426313A1 (en) | Biosurfactant formulations for use in skincare and wound treatment | |
JP2007039394A (en) | External preparation for skin for preventing and ameliorating aging | |
US20240352069A1 (en) | Synthetic peptide, and cosmetic composition or pharmaceutical composition and application thereof | |
WO2023196763A1 (en) | Therapeutic compositions for enhanced healing of wounds and scars |